1
|
Tak D, Ye Z, Zapaischykova A, Zha Y, Boyd A, Vajapeyam S, Chopra R, Hayat H, Prabhu SP, Liu KX, Elhalawani H, Nabavizadeh A, Familiar A, Resnick AC, Mueller S, Aerts HJWL, Bandopadhayay P, Ligon KL, Haas-Kogan DA, Poussaint TY, Kann BH. Noninvasive Molecular Subtyping of Pediatric Low-Grade Glioma with Self-Supervised Transfer Learning. Radiol Artif Intell 2024; 6:e230333. [PMID: 38446044 DOI: 10.1148/ryai.230333] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/07/2024]
Abstract
Purpose To develop and externally test a scan-to-prediction deep learning pipeline for noninvasive, MRI-based BRAF mutational status classification for pediatric low-grade glioma. Materials and Methods This retrospective study included two pediatric low-grade glioma datasets with linked genomic and diagnostic T2-weighted MRI data of patients: Dana-Farber/Boston Children's Hospital (development dataset, n = 214 [113 (52.8%) male; 104 (48.6%) BRAF wild type, 60 (28.0%) BRAF fusion, and 50 (23.4%) BRAF V600E]) and the Children's Brain Tumor Network (external testing, n = 112 [55 (49.1%) male; 35 (31.2%) BRAF wild type, 60 (53.6%) BRAF fusion, and 17 (15.2%) BRAF V600E]). A deep learning pipeline was developed to classify BRAF mutational status (BRAF wild type vs BRAF fusion vs BRAF V600E) via a two-stage process: (a) three-dimensional tumor segmentation and extraction of axial tumor images and (b) section-wise, deep learning-based classification of mutational status. Knowledge-transfer and self-supervised approaches were investigated to prevent model overfitting, with a primary end point of the area under the receiver operating characteristic curve (AUC). To enhance model interpretability, a novel metric, center of mass distance, was developed to quantify the model attention around the tumor. Results A combination of transfer learning from a pretrained medical imaging-specific network and self-supervised label cross-training (TransferX) coupled with consensus logic yielded the highest classification performance with an AUC of 0.82 (95% CI: 0.72, 0.91), 0.87 (95% CI: 0.61, 0.97), and 0.85 (95% CI: 0.66, 0.95) for BRAF wild type, BRAF fusion, and BRAF V600E, respectively, on internal testing. On external testing, the pipeline yielded an AUC of 0.72 (95% CI: 0.64, 0.86), 0.78 (95% CI: 0.61, 0.89), and 0.72 (95% CI: 0.64, 0.88) for BRAF wild type, BRAF fusion, and BRAF V600E, respectively. Conclusion Transfer learning and self-supervised cross-training improved classification performance and generalizability for noninvasive pediatric low-grade glioma mutational status prediction in a limited data scenario. Keywords: Pediatrics, MRI, CNS, Brain/Brain Stem, Oncology, Feature Detection, Diagnosis, Supervised Learning, Transfer Learning, Convolutional Neural Network (CNN) Supplemental material is available for this article. © RSNA, 2024.
Collapse
Affiliation(s)
- Divyanshu Tak
- From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115 (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., K.X.L., H.E., H.J.W.L.A., D.A.H.K., B.H.K.); Department of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, Mass (S.V., S.P.P., T.Y.P.); Center for Data-Driven Discovery in Biomedicine (A.N., A.F.) and Department of Neurosurgery (A.F., A.C.R.), Children's Hospital of Philadelphia, Philadelphia, Pa; Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa (A.N.); Departments of Neurology, Pediatrics, and Neurologic Surgery, University of California San Francisco, San Francisco, Calif (S.M.); Department of Radiology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass (H.J.W.L.A.); Department of Radiology and Nuclear Medicine, CalifRIM & GROW, Maastricht University, Maastricht, the Netherlands (H.J.W.L.A.); and Department of Pediatric Oncology (P.B.) and Department of Pathology (K.L.L.), Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, Mass
| | - Zezhong Ye
- From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115 (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., K.X.L., H.E., H.J.W.L.A., D.A.H.K., B.H.K.); Department of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, Mass (S.V., S.P.P., T.Y.P.); Center for Data-Driven Discovery in Biomedicine (A.N., A.F.) and Department of Neurosurgery (A.F., A.C.R.), Children's Hospital of Philadelphia, Philadelphia, Pa; Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa (A.N.); Departments of Neurology, Pediatrics, and Neurologic Surgery, University of California San Francisco, San Francisco, Calif (S.M.); Department of Radiology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass (H.J.W.L.A.); Department of Radiology and Nuclear Medicine, CalifRIM & GROW, Maastricht University, Maastricht, the Netherlands (H.J.W.L.A.); and Department of Pediatric Oncology (P.B.) and Department of Pathology (K.L.L.), Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, Mass
| | - Anna Zapaischykova
- From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115 (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., K.X.L., H.E., H.J.W.L.A., D.A.H.K., B.H.K.); Department of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, Mass (S.V., S.P.P., T.Y.P.); Center for Data-Driven Discovery in Biomedicine (A.N., A.F.) and Department of Neurosurgery (A.F., A.C.R.), Children's Hospital of Philadelphia, Philadelphia, Pa; Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa (A.N.); Departments of Neurology, Pediatrics, and Neurologic Surgery, University of California San Francisco, San Francisco, Calif (S.M.); Department of Radiology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass (H.J.W.L.A.); Department of Radiology and Nuclear Medicine, CalifRIM & GROW, Maastricht University, Maastricht, the Netherlands (H.J.W.L.A.); and Department of Pediatric Oncology (P.B.) and Department of Pathology (K.L.L.), Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, Mass
| | - Yining Zha
- From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115 (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., K.X.L., H.E., H.J.W.L.A., D.A.H.K., B.H.K.); Department of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, Mass (S.V., S.P.P., T.Y.P.); Center for Data-Driven Discovery in Biomedicine (A.N., A.F.) and Department of Neurosurgery (A.F., A.C.R.), Children's Hospital of Philadelphia, Philadelphia, Pa; Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa (A.N.); Departments of Neurology, Pediatrics, and Neurologic Surgery, University of California San Francisco, San Francisco, Calif (S.M.); Department of Radiology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass (H.J.W.L.A.); Department of Radiology and Nuclear Medicine, CalifRIM & GROW, Maastricht University, Maastricht, the Netherlands (H.J.W.L.A.); and Department of Pediatric Oncology (P.B.) and Department of Pathology (K.L.L.), Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, Mass
| | - Aidan Boyd
- From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115 (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., K.X.L., H.E., H.J.W.L.A., D.A.H.K., B.H.K.); Department of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, Mass (S.V., S.P.P., T.Y.P.); Center for Data-Driven Discovery in Biomedicine (A.N., A.F.) and Department of Neurosurgery (A.F., A.C.R.), Children's Hospital of Philadelphia, Philadelphia, Pa; Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa (A.N.); Departments of Neurology, Pediatrics, and Neurologic Surgery, University of California San Francisco, San Francisco, Calif (S.M.); Department of Radiology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass (H.J.W.L.A.); Department of Radiology and Nuclear Medicine, CalifRIM & GROW, Maastricht University, Maastricht, the Netherlands (H.J.W.L.A.); and Department of Pediatric Oncology (P.B.) and Department of Pathology (K.L.L.), Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, Mass
| | - Sridhar Vajapeyam
- From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115 (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., K.X.L., H.E., H.J.W.L.A., D.A.H.K., B.H.K.); Department of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, Mass (S.V., S.P.P., T.Y.P.); Center for Data-Driven Discovery in Biomedicine (A.N., A.F.) and Department of Neurosurgery (A.F., A.C.R.), Children's Hospital of Philadelphia, Philadelphia, Pa; Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa (A.N.); Departments of Neurology, Pediatrics, and Neurologic Surgery, University of California San Francisco, San Francisco, Calif (S.M.); Department of Radiology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass (H.J.W.L.A.); Department of Radiology and Nuclear Medicine, CalifRIM & GROW, Maastricht University, Maastricht, the Netherlands (H.J.W.L.A.); and Department of Pediatric Oncology (P.B.) and Department of Pathology (K.L.L.), Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, Mass
| | - Rishi Chopra
- From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115 (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., K.X.L., H.E., H.J.W.L.A., D.A.H.K., B.H.K.); Department of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, Mass (S.V., S.P.P., T.Y.P.); Center for Data-Driven Discovery in Biomedicine (A.N., A.F.) and Department of Neurosurgery (A.F., A.C.R.), Children's Hospital of Philadelphia, Philadelphia, Pa; Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa (A.N.); Departments of Neurology, Pediatrics, and Neurologic Surgery, University of California San Francisco, San Francisco, Calif (S.M.); Department of Radiology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass (H.J.W.L.A.); Department of Radiology and Nuclear Medicine, CalifRIM & GROW, Maastricht University, Maastricht, the Netherlands (H.J.W.L.A.); and Department of Pediatric Oncology (P.B.) and Department of Pathology (K.L.L.), Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, Mass
| | - Hasaan Hayat
- From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115 (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., K.X.L., H.E., H.J.W.L.A., D.A.H.K., B.H.K.); Department of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, Mass (S.V., S.P.P., T.Y.P.); Center for Data-Driven Discovery in Biomedicine (A.N., A.F.) and Department of Neurosurgery (A.F., A.C.R.), Children's Hospital of Philadelphia, Philadelphia, Pa; Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa (A.N.); Departments of Neurology, Pediatrics, and Neurologic Surgery, University of California San Francisco, San Francisco, Calif (S.M.); Department of Radiology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass (H.J.W.L.A.); Department of Radiology and Nuclear Medicine, CalifRIM & GROW, Maastricht University, Maastricht, the Netherlands (H.J.W.L.A.); and Department of Pediatric Oncology (P.B.) and Department of Pathology (K.L.L.), Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, Mass
| | - Sanjay P Prabhu
- From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115 (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., K.X.L., H.E., H.J.W.L.A., D.A.H.K., B.H.K.); Department of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, Mass (S.V., S.P.P., T.Y.P.); Center for Data-Driven Discovery in Biomedicine (A.N., A.F.) and Department of Neurosurgery (A.F., A.C.R.), Children's Hospital of Philadelphia, Philadelphia, Pa; Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa (A.N.); Departments of Neurology, Pediatrics, and Neurologic Surgery, University of California San Francisco, San Francisco, Calif (S.M.); Department of Radiology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass (H.J.W.L.A.); Department of Radiology and Nuclear Medicine, CalifRIM & GROW, Maastricht University, Maastricht, the Netherlands (H.J.W.L.A.); and Department of Pediatric Oncology (P.B.) and Department of Pathology (K.L.L.), Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, Mass
| | - Kevin X Liu
- From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115 (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., K.X.L., H.E., H.J.W.L.A., D.A.H.K., B.H.K.); Department of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, Mass (S.V., S.P.P., T.Y.P.); Center for Data-Driven Discovery in Biomedicine (A.N., A.F.) and Department of Neurosurgery (A.F., A.C.R.), Children's Hospital of Philadelphia, Philadelphia, Pa; Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa (A.N.); Departments of Neurology, Pediatrics, and Neurologic Surgery, University of California San Francisco, San Francisco, Calif (S.M.); Department of Radiology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass (H.J.W.L.A.); Department of Radiology and Nuclear Medicine, CalifRIM & GROW, Maastricht University, Maastricht, the Netherlands (H.J.W.L.A.); and Department of Pediatric Oncology (P.B.) and Department of Pathology (K.L.L.), Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, Mass
| | - Hesham Elhalawani
- From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115 (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., K.X.L., H.E., H.J.W.L.A., D.A.H.K., B.H.K.); Department of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, Mass (S.V., S.P.P., T.Y.P.); Center for Data-Driven Discovery in Biomedicine (A.N., A.F.) and Department of Neurosurgery (A.F., A.C.R.), Children's Hospital of Philadelphia, Philadelphia, Pa; Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa (A.N.); Departments of Neurology, Pediatrics, and Neurologic Surgery, University of California San Francisco, San Francisco, Calif (S.M.); Department of Radiology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass (H.J.W.L.A.); Department of Radiology and Nuclear Medicine, CalifRIM & GROW, Maastricht University, Maastricht, the Netherlands (H.J.W.L.A.); and Department of Pediatric Oncology (P.B.) and Department of Pathology (K.L.L.), Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, Mass
| | - Ali Nabavizadeh
- From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115 (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., K.X.L., H.E., H.J.W.L.A., D.A.H.K., B.H.K.); Department of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, Mass (S.V., S.P.P., T.Y.P.); Center for Data-Driven Discovery in Biomedicine (A.N., A.F.) and Department of Neurosurgery (A.F., A.C.R.), Children's Hospital of Philadelphia, Philadelphia, Pa; Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa (A.N.); Departments of Neurology, Pediatrics, and Neurologic Surgery, University of California San Francisco, San Francisco, Calif (S.M.); Department of Radiology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass (H.J.W.L.A.); Department of Radiology and Nuclear Medicine, CalifRIM & GROW, Maastricht University, Maastricht, the Netherlands (H.J.W.L.A.); and Department of Pediatric Oncology (P.B.) and Department of Pathology (K.L.L.), Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, Mass
| | - Ariana Familiar
- From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115 (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., K.X.L., H.E., H.J.W.L.A., D.A.H.K., B.H.K.); Department of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, Mass (S.V., S.P.P., T.Y.P.); Center for Data-Driven Discovery in Biomedicine (A.N., A.F.) and Department of Neurosurgery (A.F., A.C.R.), Children's Hospital of Philadelphia, Philadelphia, Pa; Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa (A.N.); Departments of Neurology, Pediatrics, and Neurologic Surgery, University of California San Francisco, San Francisco, Calif (S.M.); Department of Radiology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass (H.J.W.L.A.); Department of Radiology and Nuclear Medicine, CalifRIM & GROW, Maastricht University, Maastricht, the Netherlands (H.J.W.L.A.); and Department of Pediatric Oncology (P.B.) and Department of Pathology (K.L.L.), Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, Mass
| | - Adam C Resnick
- From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115 (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., K.X.L., H.E., H.J.W.L.A., D.A.H.K., B.H.K.); Department of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, Mass (S.V., S.P.P., T.Y.P.); Center for Data-Driven Discovery in Biomedicine (A.N., A.F.) and Department of Neurosurgery (A.F., A.C.R.), Children's Hospital of Philadelphia, Philadelphia, Pa; Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa (A.N.); Departments of Neurology, Pediatrics, and Neurologic Surgery, University of California San Francisco, San Francisco, Calif (S.M.); Department of Radiology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass (H.J.W.L.A.); Department of Radiology and Nuclear Medicine, CalifRIM & GROW, Maastricht University, Maastricht, the Netherlands (H.J.W.L.A.); and Department of Pediatric Oncology (P.B.) and Department of Pathology (K.L.L.), Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, Mass
| | - Sabine Mueller
- From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115 (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., K.X.L., H.E., H.J.W.L.A., D.A.H.K., B.H.K.); Department of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, Mass (S.V., S.P.P., T.Y.P.); Center for Data-Driven Discovery in Biomedicine (A.N., A.F.) and Department of Neurosurgery (A.F., A.C.R.), Children's Hospital of Philadelphia, Philadelphia, Pa; Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa (A.N.); Departments of Neurology, Pediatrics, and Neurologic Surgery, University of California San Francisco, San Francisco, Calif (S.M.); Department of Radiology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass (H.J.W.L.A.); Department of Radiology and Nuclear Medicine, CalifRIM & GROW, Maastricht University, Maastricht, the Netherlands (H.J.W.L.A.); and Department of Pediatric Oncology (P.B.) and Department of Pathology (K.L.L.), Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, Mass
| | - Hugo J W L Aerts
- From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115 (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., K.X.L., H.E., H.J.W.L.A., D.A.H.K., B.H.K.); Department of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, Mass (S.V., S.P.P., T.Y.P.); Center for Data-Driven Discovery in Biomedicine (A.N., A.F.) and Department of Neurosurgery (A.F., A.C.R.), Children's Hospital of Philadelphia, Philadelphia, Pa; Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa (A.N.); Departments of Neurology, Pediatrics, and Neurologic Surgery, University of California San Francisco, San Francisco, Calif (S.M.); Department of Radiology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass (H.J.W.L.A.); Department of Radiology and Nuclear Medicine, CalifRIM & GROW, Maastricht University, Maastricht, the Netherlands (H.J.W.L.A.); and Department of Pediatric Oncology (P.B.) and Department of Pathology (K.L.L.), Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, Mass
| | - Pratiti Bandopadhayay
- From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115 (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., K.X.L., H.E., H.J.W.L.A., D.A.H.K., B.H.K.); Department of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, Mass (S.V., S.P.P., T.Y.P.); Center for Data-Driven Discovery in Biomedicine (A.N., A.F.) and Department of Neurosurgery (A.F., A.C.R.), Children's Hospital of Philadelphia, Philadelphia, Pa; Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa (A.N.); Departments of Neurology, Pediatrics, and Neurologic Surgery, University of California San Francisco, San Francisco, Calif (S.M.); Department of Radiology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass (H.J.W.L.A.); Department of Radiology and Nuclear Medicine, CalifRIM & GROW, Maastricht University, Maastricht, the Netherlands (H.J.W.L.A.); and Department of Pediatric Oncology (P.B.) and Department of Pathology (K.L.L.), Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, Mass
| | - Keith L Ligon
- From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115 (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., K.X.L., H.E., H.J.W.L.A., D.A.H.K., B.H.K.); Department of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, Mass (S.V., S.P.P., T.Y.P.); Center for Data-Driven Discovery in Biomedicine (A.N., A.F.) and Department of Neurosurgery (A.F., A.C.R.), Children's Hospital of Philadelphia, Philadelphia, Pa; Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa (A.N.); Departments of Neurology, Pediatrics, and Neurologic Surgery, University of California San Francisco, San Francisco, Calif (S.M.); Department of Radiology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass (H.J.W.L.A.); Department of Radiology and Nuclear Medicine, CalifRIM & GROW, Maastricht University, Maastricht, the Netherlands (H.J.W.L.A.); and Department of Pediatric Oncology (P.B.) and Department of Pathology (K.L.L.), Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, Mass
| | - Daphne A Haas-Kogan
- From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115 (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., K.X.L., H.E., H.J.W.L.A., D.A.H.K., B.H.K.); Department of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, Mass (S.V., S.P.P., T.Y.P.); Center for Data-Driven Discovery in Biomedicine (A.N., A.F.) and Department of Neurosurgery (A.F., A.C.R.), Children's Hospital of Philadelphia, Philadelphia, Pa; Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa (A.N.); Departments of Neurology, Pediatrics, and Neurologic Surgery, University of California San Francisco, San Francisco, Calif (S.M.); Department of Radiology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass (H.J.W.L.A.); Department of Radiology and Nuclear Medicine, CalifRIM & GROW, Maastricht University, Maastricht, the Netherlands (H.J.W.L.A.); and Department of Pediatric Oncology (P.B.) and Department of Pathology (K.L.L.), Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, Mass
| | - Tina Y Poussaint
- From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115 (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., K.X.L., H.E., H.J.W.L.A., D.A.H.K., B.H.K.); Department of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, Mass (S.V., S.P.P., T.Y.P.); Center for Data-Driven Discovery in Biomedicine (A.N., A.F.) and Department of Neurosurgery (A.F., A.C.R.), Children's Hospital of Philadelphia, Philadelphia, Pa; Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa (A.N.); Departments of Neurology, Pediatrics, and Neurologic Surgery, University of California San Francisco, San Francisco, Calif (S.M.); Department of Radiology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass (H.J.W.L.A.); Department of Radiology and Nuclear Medicine, CalifRIM & GROW, Maastricht University, Maastricht, the Netherlands (H.J.W.L.A.); and Department of Pediatric Oncology (P.B.) and Department of Pathology (K.L.L.), Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, Mass
| | - Benjamin H Kann
- From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115 (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., K.X.L., H.E., H.J.W.L.A., D.A.H.K., B.H.K.); Department of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, Mass (S.V., S.P.P., T.Y.P.); Center for Data-Driven Discovery in Biomedicine (A.N., A.F.) and Department of Neurosurgery (A.F., A.C.R.), Children's Hospital of Philadelphia, Philadelphia, Pa; Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa (A.N.); Departments of Neurology, Pediatrics, and Neurologic Surgery, University of California San Francisco, San Francisco, Calif (S.M.); Department of Radiology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass (H.J.W.L.A.); Department of Radiology and Nuclear Medicine, CalifRIM & GROW, Maastricht University, Maastricht, the Netherlands (H.J.W.L.A.); and Department of Pediatric Oncology (P.B.) and Department of Pathology (K.L.L.), Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, Mass
| |
Collapse
|
2
|
Liu LP, Zha Y, Wang JY, Xu LY, Qin X. [Role of innate lymphoid cells in oral squamous cell carcinoma microenvironment]. Zhonghua Kou Qiang Yi Xue Za Zhi 2024; 59:394-399. [PMID: 38548598 DOI: 10.3760/cma.j.cn112144-20240129-00041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 04/13/2024]
Abstract
Oral squamous cell carcinoma (OSCC) is the most common oral malignancy. It has a high incidence, strong invasion ability, easy metastasis, poor curative effect, and poor prognosis. Innate lymphoid cells (ILCs) are an important part of immune cells located in the mucosal barrier, which play an important role in the occurrence, development and outcome of tumors. ILCs are the key cells for decoding the regulatory mechanism of tumor microenvironment and the signatures for tumor progression. This paper reviewed the latest progress on ILCs, summarized the possible characteristics and functions of ILCs in the microenvironment of OSCC, and explored the relationship between ILCs and the occurrence, development and immunotherapy of OSCC.
Collapse
Affiliation(s)
- L P Liu
- School of Stomatology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
| | - Y Zha
- School of Stomatology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
| | - J Y Wang
- School of Stomatology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
| | - L Y Xu
- Department of Stomatology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology & School of Stomatology, Tongji Medical College, Huazhong University of Science and Technology & Hubei Province Key Laboratory of Oral and Maxillofacial Development and Regeneration, Wuhan 430030, China
| | - X Qin
- Department of Stomatology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology & School of Stomatology, Tongji Medical College, Huazhong University of Science and Technology & Hubei Province Key Laboratory of Oral and Maxillofacial Development and Regeneration, Wuhan 430030, China
| |
Collapse
|
3
|
Yu J, Da J, Yu F, Yuan J, Zha Y. HMGN1 down-regulation in the diabetic kidney attenuates tubular cells injury and protects against renal inflammation via suppressing MCP-1 and KIM-1 expression through TLR4. J Endocrinol Invest 2024; 47:1015-1027. [PMID: 38409569 DOI: 10.1007/s40618-023-02292-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/17/2023] [Accepted: 12/20/2023] [Indexed: 02/28/2024]
Abstract
BACKGROUND Renal tubular injury, accompanied by damaging inflammation, has been identified to drive diabetic kidney disease (DKD) toward end-stage renal disease. However, it is unclear how damage-associated molecular patterns (DAMPs) activate innate immunity to mediate tubular epithelial cell (TEC) injury, which in turn causes with subsequent sterile inflammation in diabetic kidneys. High mobility group nucleosome-binding protein 1 (HMGN1) is a novel DAMP that contributes to generating the innate immune response. In this study, we focused on determining whether HMGN1 is involved in DKD progression. METHODS Streptozotocin (STZ)-induced diabetic mice model was established. Then we downrergulated HMGN1 expression in kidney with or without HMGN1 administration. The renal dysfunction and morphological lesions in the kidneys were evaluated. The expressions of KIM-1, MCP-1, F4/80, CD68, and HMGN1/TLR4 signaling were examined in the renal tissue. In vitro, HK2 cells were exposed in the high glucose with or without HMGN1, and further pre-incubated with TAK242 was applied to elucidate the underlying mechanism. RESULTS We demonstrated that HMGN1 was upregulated in the tubular epithelial cells of streptozotocin (STZ)-induced type 1 and type 2 diabetic mouse kidneys compared to controls, while being positively correlated with increased TLR4, KIM-1, and MCP-1. Down-regulation of renal HMGN1 attenuated diabetic kidney injury, decreased the TLR4, KIM-1, and MCP-1 expression levels, and reduced interstitial infiltrating macrophages. However, these phenotypes were reversed after administration of HMGN1. In HK-2 cells, HMGN1 promoted the expression of KIM-1 and MCP-1 via regulating MyD88/NF-κB pathway; inhibition of TLR4 effectively diminished the in vitro response to HMGN1. CONCLUSIONS Our study provides novel insight into HMGN1 signaling mechanisms that contribute to tubular sterile injury and low-grade inflammation in DKD. The study findings may help to develop new HMGN1-targeted approaches as therapy for immune-mediated kidney damage rather than as an anti-infection treatments.
Collapse
Affiliation(s)
- J Yu
- School of Medicine, Guizhou University, Guiyang, Guizhou, China
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China
| | - J Da
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China
| | - F Yu
- School of Medicine, Guizhou University, Guiyang, Guizhou, China
- NHC Key Laboratory of Pulmonary Immunological Disease, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China
| | - J Yuan
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China
| | - Y Zha
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China.
- NHC Key Laboratory of Pulmonary Immunological Disease, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China.
| |
Collapse
|
4
|
Lan Q, Tian ML, Yuan J, Tong XY, Long CZ, Zha Y. [Association of waist-to-height ratio with sarcopenic obesity in hemodialysis patients with normal body mass index]. Zhonghua Yi Xue Za Zhi 2024; 104:931-937. [PMID: 38514341 DOI: 10.3760/cma.j.cn112137-20230902-00376] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 03/23/2024]
Abstract
Objective: To explore the association between waist-to-height ratio (WHtR) and sarcopenic obesity (SO) in maintenance hemodialysis (MHD) patients with normal body mass index (BMI). Methods: A multicenter and cross-sectional study that included adult patients undergoing MHD was conducted in 20 hemodialysis centers from June 1st to August 30th, 2021. Body composition was evaluated by body composition monitor based on bioimpedance spectroscopy. According to the quartiles of WHtR, patients were divided into four groups: Q1, Q2, Q3 and Q4 group. The association of WHtR with SO was determined by multiple logistic regression models, stratified analyses, interactive analyses, and receiver operating characteristic (ROC) analyses, respectively. Results: A total of 2 207 MHD patients (1 341 males and 866 females) were included, and aged [M (Q1, Q3)] 57 (44, 68) years. The prevalence of SO was increased with increasing quartiles of WHtR [8.6% (46/533), 22.5% (141/628), 35.4% (215/608), and 44.3% (194/438) for Q1, Q2, Q3, and Q4 group, respectively]. Multivariate logistic regression analysis showed that WHtR was associated with SO. The association remained statistically significant even after adjusting for age, gender, dialysis vintage, BMI, biochemical indicators, and various medical histories. Compared with Q1 group, the odds ratios (OR) were 2.54 (95%CI: 1.69-3.83), 4.30 (95%CI: 2.88-6.42) and 5.18 (95%CI: 3.37-7.96) for Q2, Q3 and Q4 group, respectively. The interaction analysis showed that age, sex and history of diabetes had interactive roles in the association between WHtR and SO (all P<0.05). The association stably existed across subgroups, and it was more obvious in male patients, those with older age and without a history of diabetes(all P<0.05). Furthermore, the cut-off value of WHtR identifying SO in male patients was 0.49, and the corresponding area under the curve (AUC) was 0.73 (95%CI: 0.70-0.75), with the sensitivity of 72.7% and specificity of 60.3%. In female patients, the cut-off value was 0.51, and the AUC was 0.68 (95%CI: 0.65-0.71), with the sensitivity of 70.1% and specificity of 57.8%. Conclusion: WHtR could be used as a simple index to evaluate the risk of SO in MHD patients with normal BMI.
Collapse
Affiliation(s)
- Q Lan
- Graduate School of Zunyi Medical University, Zunyi 563000, China
| | - M L Tian
- Department of Nephrology, Guizhou Provincial People's Hospital, Key Laboratory of Diagnosis and Treatment of Pulmonary Immune Diseases, National Health Commission, Guiyang 550002, China
| | - J Yuan
- Department of Nephrology, Guizhou Provincial People's Hospital, Key Laboratory of Diagnosis and Treatment of Pulmonary Immune Diseases, National Health Commission, Guiyang 550002, China
| | - X Y Tong
- Department of Nephrology, Guizhou Provincial People's Hospital, Key Laboratory of Diagnosis and Treatment of Pulmonary Immune Diseases, National Health Commission, Guiyang 550002, China
| | - C Z Long
- Department of Nephrology, Guizhou Provincial People's Hospital, Key Laboratory of Diagnosis and Treatment of Pulmonary Immune Diseases, National Health Commission, Guiyang 550002, China
| | - Y Zha
- Department of Nephrology, Guizhou Provincial People's Hospital, Key Laboratory of Diagnosis and Treatment of Pulmonary Immune Diseases, National Health Commission, Guiyang 550002, China
| |
Collapse
|
5
|
Tak D, Ye Z, Zapaishchykova A, Zha Y, Boyd A, Vajapeyam S, Chopra R, Hayat H, Prabhu S, Liu KX, Elhalawani H, Nabavizadeh A, Familiar A, Resnick A, Mueller S, Aerts HJ, Bandopadhayay P, Ligon K, Haas-Kogan D, Poussaint T, Kann BH. Noninvasive molecular subtyping of pediatric low-grade glioma with self-supervised transfer learning. medRxiv 2023:2023.08.04.23293673. [PMID: 37609311 PMCID: PMC10441478 DOI: 10.1101/2023.08.04.23293673] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 08/24/2023]
Abstract
Purpose To develop and externally validate a scan-to-prediction deep-learning pipeline for noninvasive, MRI-based BRAF mutational status classification for pLGG. Materials and Methods We conducted a retrospective study of two pLGG datasets with linked genomic and diagnostic T2-weighted MRI of patients: BCH (development dataset, n=214 [60 (28%) BRAF fusion, 50 (23%) BRAF V600E, 104 (49%) wild-type), and Child Brain Tumor Network (CBTN) (external validation, n=112 [60 (53%) BRAF-Fusion, 17 (15%) BRAF-V600E, 35 (32%) wild-type]). We developed a deep learning pipeline to classify BRAF mutational status (V600E vs. fusion vs. wildtype) via a two-stage process: 1) 3D tumor segmentation and extraction of axial tumor images, and 2) slice-wise, deep learning-based classification of mutational status. We investigated knowledge-transfer and self-supervised approaches to prevent model overfitting with a primary endpoint of the area under the receiver operating characteristic curve (AUC). To enhance model interpretability, we developed a novel metric, COMDist, that quantifies the accuracy of model attention around the tumor. Results A combination of transfer learning from a pretrained medical imaging-specific network and self-supervised label cross-training (TransferX) coupled with consensus logic yielded the highest macro-average AUC (0.82 [95% CI: 0.70-0.90]) and accuracy (77%) on internal validation, with an AUC improvement of +17.7% and a COMDist improvement of +6.4% versus training from scratch. On external validation, the TransferX model yielded AUC (0.73 [95% CI 0.68-0.88]) and accuracy (75%). Conclusion Transfer learning and self-supervised cross-training improved classification performance and generalizability for noninvasive pLGG mutational status prediction in a limited data scenario.
Collapse
Affiliation(s)
- Divyanshu Tak
- Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, USA
- Department of Radiation Oncology, Dana-Farber Cancer Institute | Brigham and Women’s Hospital | Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA
| | - Zezhong Ye
- Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, USA
- Department of Radiation Oncology, Dana-Farber Cancer Institute | Brigham and Women’s Hospital | Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA
| | - Anna Zapaishchykova
- Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, USA
- Department of Radiation Oncology, Dana-Farber Cancer Institute | Brigham and Women’s Hospital | Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA
| | - Yining Zha
- Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, USA
- Department of Radiation Oncology, Dana-Farber Cancer Institute | Brigham and Women’s Hospital | Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA
| | - Aidan Boyd
- Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, USA
- Department of Radiation Oncology, Dana-Farber Cancer Institute | Brigham and Women’s Hospital | Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA
| | - Sridhar Vajapeyam
- Department of Radiology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA
| | - Rishi Chopra
- Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, USA
- Department of Radiation Oncology, Dana-Farber Cancer Institute | Brigham and Women’s Hospital | Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA
| | - Hasaan Hayat
- Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, USA
- Department of Radiation Oncology, Dana-Farber Cancer Institute | Brigham and Women’s Hospital | Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA
| | - Sanjay Prabhu
- Department of Radiology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA
| | - Kevin X. Liu
- Department of Radiation Oncology, Dana-Farber Cancer Institute | Brigham and Women’s Hospital | Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA
| | - Hesham Elhalawani
- Department of Radiation Oncology, Dana-Farber Cancer Institute | Brigham and Women’s Hospital | Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA
| | - Ali Nabavizadeh
- Center for Data-Driven Discovery in Biomedicine (D3b), Children’s Hospital of Philadelphia, Philadelphia, PA, USA
- Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Ariana Familiar
- Center for Data-Driven Discovery in Biomedicine (D3b), Children’s Hospital of Philadelphia, Philadelphia, PA, USA
- Department of Neurosurgery, Children’s Hospital of Philadelphia, Philadelphia, PA, USA
| | - Adam Resnick
- Department of Neurosurgery, Children’s Hospital of Philadelphia, Philadelphia, PA, USA
| | - Sabine Mueller
- Department of Neurology, University of California San Francisco, San Francisco, CA. USA
- Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA
- Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA
| | - Hugo J.W.L. Aerts
- Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, USA
- Department of Radiation Oncology, Dana-Farber Cancer Institute | Brigham and Women’s Hospital | Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA
- Department of Radiology, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
- Radiology and Nuclear Medicine, CARIM & GROW, Maastricht University, Maastricht, the Netherlands
| | - Pratiti Bandopadhayay
- Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA
| | - Keith Ligon
- Department of Pathology, Dana-Farber Cancer Institute, Boston Children’s Hospital, Harvard Medical School, Boston, A, USA
| | - Daphne Haas-Kogan
- Department of Radiation Oncology, Dana-Farber Cancer Institute | Brigham and Women’s Hospital | Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA
| | - Tina Poussaint
- Department of Radiology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA
| | - Benjamin H. Kann
- Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, USA
- Department of Radiation Oncology, Dana-Farber Cancer Institute | Brigham and Women’s Hospital | Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA
| |
Collapse
|
6
|
Gupta AC, Cazoulat G, Zha Y, Al Tae M, Yedururi S, Castelo A, Wood J, He Y, McCulloch MM, Paolucci I, O'Connor C, Koay EJ, Brock KK. Statistical Analysis to Determine the Predictors of Liver Segmental Hypertrophy Observed Post-Radiotherapy. Int J Radiat Oncol Biol Phys 2023; 117:e667. [PMID: 37785970 DOI: 10.1016/j.ijrobp.2023.06.2109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Prediction of liver segment hypertrophy based on radiotherapy (RT) dose is crucial for maximizing functional liver volume and avoiding hepatic failure after RT. We determined predictors associated with liver hypertrophy with stratification based on induction chemo (IC) and tumor location. MATERIALS/METHODS RT planning, CT images, and 3-month-followup CTs were analyzed from 148 patients who underwent RT for primary or metastatic liver cancers. A nnUNet based model was trained (train/test = 160/40 CTs) to contour the liver segments (1, 2, 3, 4, 5-8) with accuracy assessed using Dice Similarity Coefficients (DSC). 52 features corresponding to segments 1, 2, 3, 2+3, 4, 5-8, were collected including equivalent dose to 2Gy fractions metrics-mean dose (Dmean), dose received by 95% of the volume (D95), volume spared from x gy (Vx), cancer type, tumor location, and IC status. Descriptive statistics were reported as percentage of segments showing hypertrophy under all stratification. Predictors were compared with 6 response variables using Chi-squared/Fisher-Exact test (CST/FET) and logistic regression (LR) for categorical and numerical predictors. RESULTS The nnUNet model had an average DSC of 0.91 across all segments. Overall, segments 1, 4, and 5-8 showed hypertrophy in 35% of cases, and segments 2, 3 and 2+3 showed hypertrophy in 45-49% of patients. Stratification based on tumor location resulted in segment 2+3 hypertrophy in 66% of patients when the tumor was in segments 5-8. For bilobed tumors, segment 2+3 hypertrophy was observed in 34% of patients. CST/FET showed that tumor location, IC, and tumor type were significant predictors of segment 5-8 hypertrophy. Tumor location was also a significant predictor of segments 3 and 2+3 hypertrophy. In LR analysis, all segment-based dose metrics were significant predictors of segment hypertrophy except Dmean in segment 4, and D95 in segment 2 and 4. Overall, the strongest association was obtained for V35 significantly predicting for each segment hypertrophy. The mean dose for segments with hypertrophy was significantly lower (range: 15-30 Gy) than segments with atrophy (p<0.01), except for segment 4 where the mean dose was 10Gy lower but did not reach significance. IC impacts the threshold mean dose that leads to hypertrophy, with more toxic drugs reducing the mean dose threshold. CONCLUSION Tumor location and IC significantly impact the response of segments to RT. Dose volume metrics are strong predictors of volumetric response with segment volume spared from 35 Gy being the strongest predictor.
Collapse
Affiliation(s)
- A C Gupta
- UT MD Anderson Cancer Center, Houston, TX
| | - G Cazoulat
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Y Zha
- UT MD Anderson Cancer Center, Houston, TX
| | - M Al Tae
- UT MD Anderson Cancer Center, Houston, TX
| | - S Yedururi
- UT MD Anderson Cancer Center, Houston, TX
| | - A Castelo
- UT MD Anderson Cancer Center, Houston, TX
| | - J Wood
- UT MD Anderson Cancer Center, Houston, TX
| | - Y He
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - M M McCulloch
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - I Paolucci
- UT MD Anderson Cancer Center, Houston, TX
| | - C O'Connor
- UT MD Anderson Cancer Center, Houston, TX
| | - E J Koay
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - K K Brock
- The University of Texas MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
7
|
Spurr LF, Martinez C, Kang W, Chen M, Zha Y, Hseu R, Gutiontov S, Turchan WT, Lynch C, Pointer KB, Vokes EE, Bestvina CM, Patel JD, Diehn M, Weichselbaum RR, Chmura SJ, Pitroda SP. Concurrent Radiation and Immunotherapy Augments Local Immunity and Improves Survival in Aneuploid NSCLC. Int J Radiat Oncol Biol Phys 2023; 117:S23. [PMID: 37784457 DOI: 10.1016/j.ijrobp.2023.06.279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Over 500 clinical trials combining radiation (RT) and immune checkpoint blockade (ICB) have been initiated based on preclinical evidence that RT can augment local immunity and improve the efficacy of ICB. However, many recent clinical trials have not found a benefit of combining RT and ICB, raising questions about whether a synergy exists. We examined whether RT and ICB interact to beneficially stimulate the immune response in patients and identified biomarkers of response to RT and ICB. MATERIALS/METHODS We performed a molecular analysis of 1,740 patients from 3 cohorts. The COSINR dataset is a randomized clinical trial of 22 non-small cell lung cancer (NSCLC) patients treated with concurrent or sequential SBRT and ipilimumab/nivolumab. Paired pre- and on-treatment biopsies of an irradiated metastasis underwent whole exome sequencing and RNA-seq. On-treatment biopsies were obtained after SBRT and prior to ICB (sequential) or after SBRT and one cycle of ICB (concurrent). The UC cohort consisted of targeted DNA sequencing of 58 NSCLC patients treated with ICB alone, sequential RT+ICB, or concurrent RT+ICB. The MSKCC dataset is a pan-cancer cohort of targeted DNA sequencing of 1,660 patients treated with ICB. Aneuploidy score (AS) was defined as the fraction of chromosome arms with arm-level copy number alterations. Survival analyses utilized the Kaplan-Meier method and multivariable Cox proportional hazards models. RESULTS In the COSINR trial, SBRT+ICB increased, whereas SBRT alone decreased, expression of effector T cell IFN-gamma and adaptive immune signatures (P<0.05). Established biomarkers of ICB response, including IFN-gamma signature, tumor mutational burden (TMB), PD-L1 expression, and neoantigen burden were not associated with survival (P>0.05). However, patients whose tumors exhibited high (≥median) but not low, AS had improved survival when treated with concurrent vs. sequential SBRT+ICB (1-year overall survival [OS] 100% vs. 17%, P = 0.025). Our findings were corroborated in the UC cohort: high AS tumors treated with RT + ICB had superior 1-year OS compared to those treated with ICB alone (59% vs. 31%, P = 0.021). Among those who received RT + ICB, concurrent treatment improved OS relative to sequential (1-year OS 76% vs. 38%). RT did not improve OS in patients with low ( CONCLUSION Our findings distinguish the genomic and transcriptomic effects of RT versus RT+ICB and challenge the prevailing paradigm that local ablative RT positively stimulates the immune response. We propose the use of tumor aneuploidy as a biomarker in personalizing treatment approaches for patients with various cancers.
Collapse
Affiliation(s)
| | | | - W Kang
- University of Chicago, Chicago, IL
| | - M Chen
- University of Chicago, Chicago, IL
| | - Y Zha
- University of Chicago, Chicago, IL
| | - R Hseu
- University of Chicago, Chicago, IL
| | - S Gutiontov
- Department of Radiation and Cellular Oncology, University of Chicago Medical Center, Chicago, IL
| | | | - C Lynch
- Northwestern University Feinberg School of Medicine, Chicago, IL
| | - K B Pointer
- University of Wisconsin-Madison, Madison, WI
| | - E E Vokes
- Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL
| | - C M Bestvina
- Department of Hematology Oncology, University of Chicago Medical Center, Chicago, IL
| | - J D Patel
- Lurie Cancer Center, Northwestern University-Feinberg School of Medicine, Chicago, IL
| | - M Diehn
- Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA
| | - R R Weichselbaum
- Department of Radiation and Cellular Oncology, The University of Chicago Medicine, Chicago, IL
| | - S J Chmura
- Department of Medicine, University of North Carolina, Chapel Hill, NC
| | - S P Pitroda
- Department of Radiation and Cellular Oncology, University of Chicago Medical Center, Chicago, IL
| |
Collapse
|
8
|
Saraf A, Ye Z, Likitlersuang J, Hoebers F, Tishler RB, Schoenfeld JD, Margalit DN, Haddad RI, Ravipati Y, Zha Y, Naser M, Wahid KA, Mak RH, Mäkitie A, Kaski K, Aerts H, Fuller CD, Kann BH. Automated Sarcopenia Assessment and Outcomes in Head and Neck Cancer with Deep Learning Analysis of Cervical Neck Skeletal Muscle. Int J Radiat Oncol Biol Phys 2023; 117:e623. [PMID: 37785866 DOI: 10.1016/j.ijrobp.2023.06.2009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Sarcopenia is an established prognostic factor in patients diagnosed with head and neck cancers (HNC), typically measured by the skeletal muscle index (SMI) from abdominal muscle mass at L3. While sarcopenia assessment could inform HNC management, it remains impractical, time- and labor-intensive, and operator-dependent. To overcome these challenges, we developed an automated deep learning (DL) platform to calculate SMI at L3 by quantifying cross-sectional cervical skeletal muscle area (SMA) at C3 through auto-segmentation, externally validated it, and evaluated associations with clinical outcomes. MATERIALS/METHODS Eight hundred twenty-one patients diagnosed with HNC from multiple institutes from 1999-2013, treated with definitive chemoradiation with baseline pre-treatment CT scans, were included for model development (335 training, 96 tuning) and for independent testing (48 internal, and 342 external). Ground truth single-slice segmentations of SM at the mid-C3 vertebral level were manually annotated by radiation oncologists using an established protocol. A multi-stage DL pipeline was developed, with a 2D DenseNet to select the middle slice of C3 section and a 2D UNet to segment the SM, from which SMA was calculated. The model was evaluated using the Dice Similarity Coefficient (DC) for the internal test set, and human acceptability testing on the external test set was performed by two radiation oncologists not involved in annotations. SMI was calculated from C3 SMA based on prior literature, and sarcopenia was defined by an established, sex-specific SMI cutoff. Sarcopenia associations with overall survival (OS) and toxicities were assessed on the external dataset with Cox and logistic multivariable regressions, as indicated. RESULTS Model DC on the internal test set as 0.90 [95% CI: 0.90-0.91], with an intra-class coefficient of 0.96 for SMA. Human acceptability testing showed a pass rate of 94.4%. Of the 342 patients in the clinical analysis, 261 (76.3%) patients had sarcopenia. Five-year survival was 84.4% in patients without sarcopenia vs 73.1% in patients with sarcopenia (HR 2.21, p = 0.028) (median f/u: 44 mo (IQR: 25 - 66 mo)). On multivariable regression, sarcopenia (HR 2.06, p = 0.037), ACE-27 score 2+ (HR 2.25, p = 0.001), non-oropharynx diagnosis (HR 3.96, p<0.001), and T3-4 stage (HR 2.37, p<0.001) were associated with worse OS. Sarcopenia was associated with longer PEG tube duration on multivariable analysis (HR 1.59, p = 0.003), along with ACE-27 score (HR 1.20, p = 0.012) and non-oropharynx primary site (HR 1.46, p = 0.034). Sarcopenia was associated with higher risk of having PEG tube at last follow up (OR 2.25, p = 0.046). An observed increase in risk of hospitalization <3 months after RT was non-significant (OR 2.18, p = 0.117). CONCLUSION We developed and externally validated a fully-automated platform for sarcopenia assessment that can be used on routine HNC imaging. This algorithm is positioned for prospective testing to determine if use will inform HNC management.
Collapse
Affiliation(s)
- A Saraf
- Brigham and Women's Hospital/Dana Farber Cancer Institute, Boston, MA; Harvard Radiation Oncology Program, Boston, MA
| | - Z Ye
- Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA
| | - J Likitlersuang
- Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA
| | - F Hoebers
- Brigham and Women's Hospital, Boston, MA
| | - R B Tishler
- Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
| | - J D Schoenfeld
- Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
| | - D N Margalit
- Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
| | - R I Haddad
- Dana-Farber Cancer Institute, Boston, MA
| | - Y Ravipati
- Brigham and Women's Hospital, Boston, MA
| | - Y Zha
- Brigham and Women's Hospital, Boston, MA
| | - M Naser
- MD Anderson Cancer Center, Houston, TX
| | - K A Wahid
- MD Anderson Cancer Center, Houston, TX
| | - R H Mak
- Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA
| | - A Mäkitie
- Department of Otorhinolaryngology - Head and Neck Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
| | - K Kaski
- Aalto University School of Science, Aalto, Finland
| | - H Aerts
- Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA
| | - C D Fuller
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - B H Kann
- Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
| |
Collapse
|
9
|
Boyd A, Ye Z, Prabhu S, Tjong MC, Zha Y, Zapaishchykova A, Vajapeyam S, Hayat H, Chopra R, Liu KX, Nabavidazeh A, Resnick A, Mueller S, Haas-Kogan D, Aerts HJ, Poussaint T, Kann BH. Expert-level pediatric brain tumor segmentation in a limited data scenario with stepwise transfer learning. medRxiv 2023:2023.06.29.23292048. [PMID: 37425854 PMCID: PMC10327271 DOI: 10.1101/2023.06.29.23292048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 07/11/2023]
Abstract
Purpose Artificial intelligence (AI)-automated tumor delineation for pediatric gliomas would enable real-time volumetric evaluation to support diagnosis, treatment response assessment, and clinical decision-making. Auto-segmentation algorithms for pediatric tumors are rare, due to limited data availability, and algorithms have yet to demonstrate clinical translation. Methods We leveraged two datasets from a national brain tumor consortium (n=184) and a pediatric cancer center (n=100) to develop, externally validate, and clinically benchmark deep learning neural networks for pediatric low-grade glioma (pLGG) segmentation using a novel in-domain, stepwise transfer learning approach. The best model [via Dice similarity coefficient (DSC)] was externally validated and subject to randomized, blinded evaluation by three expert clinicians wherein clinicians assessed clinical acceptability of expert- and AI-generated segmentations via 10-point Likert scales and Turing tests. Results The best AI model utilized in-domain, stepwise transfer learning (median DSC: 0.877 [IQR 0.715-0.914]) versus baseline model (median DSC 0.812 [IQR 0.559-0.888]; p<0.05). On external testing (n=60), the AI model yielded accuracy comparable to inter-expert agreement (median DSC: 0.834 [IQR 0.726-0.901] vs. 0.861 [IQR 0.795-0.905], p=0.13). On clinical benchmarking (n=100 scans, 300 segmentations from 3 experts), the experts rated the AI model higher on average compared to other experts (median Likert rating: 9 [IQR 7-9]) vs. 7 [IQR 7-9], p<0.05 for each). Additionally, the AI segmentations had significantly higher (p<0.05) overall acceptability compared to experts on average (80.2% vs. 65.4%). Experts correctly predicted the origins of AI segmentations in an average of 26.0% of cases. Conclusions Stepwise transfer learning enabled expert-level, automated pediatric brain tumor auto-segmentation and volumetric measurement with a high level of clinical acceptability. This approach may enable development and translation of AI imaging segmentation algorithms in limited data scenarios.
Collapse
Affiliation(s)
- Aidan Boyd
- Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
| | - Zezhong Ye
- Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
| | - Sanjay Prabhu
- Department of Radiology, Boston Children’s Hospital, Harvard Medical School, Boston, MA
| | - Michael C. Tjong
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
| | - Yining Zha
- Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
| | - Anna Zapaishchykova
- Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
| | - Sridhar Vajapeyam
- Department of Radiology, Boston Children’s Hospital, Harvard Medical School, Boston, MA
| | - Hasaan Hayat
- Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
| | - Rishi Chopra
- Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
| | - Kevin X. Liu
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
| | - Ali Nabavidazeh
- Center for Data-Driven Discovery in Biomedicine (D3b), Children’s Hospital of Philadelphia, Philadelphia, PA
- Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
| | - Adam Resnick
- Center for Data-Driven Discovery in Biomedicine (D3b), Children’s Hospital of Philadelphia, Philadelphia, PA
- Department of Neurosurgery, Children’s Hospital of Philadelphia, Philadelphia, PA
| | - Sabine Mueller
- Department of Neurology, University of California San Francisco, San Francisco, California
- Department of Pediatrics, University of California San Francisco, San Francisco, California
- Department of Neurological Surgery, University of California San Francisco, San Francisco, California
| | - Daphne Haas-Kogan
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
| | - Hugo J.W.L. Aerts
- Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
- Department of Radiology, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
- Radiology and Nuclear Medicine, CARIM & GROW, Maastricht University, Maastricht, the Netherlands
| | - Tina Poussaint
- Department of Radiology, Boston Children’s Hospital, Harvard Medical School, Boston, MA
| | - Benjamin H. Kann
- Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
| |
Collapse
|
10
|
Peng YZ, Shuai D, Zhou CM, Yuan J, Zha Y. [Association between extracellular water/body cell mass ratio and cognitive impairment in patients on maintenance hemodialysis]. Zhonghua Yi Xue Za Zhi 2023; 103:2522-2528. [PMID: 37650199 DOI: 10.3760/cma.j.cn112137-20230403-00531] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 09/01/2023]
Abstract
Objective: To explore the correlation between extracellular water/body cell mass (ECW/BCM) ratio and cognitive impairment (CI) in patients on maintenance hemodialysis (MHD). Methods: A multicenter, cross-sectional study was conducted in Guizhou Province. All adult MHD patients in hemodialysis centers of 18 hospitals in Guizhou Province between June and October 2020 were included. Cognitive function was assessed with the Mini-Mental State Examination (MMSE) score. The ECW and BCM was derived from bioelectrical impedance, and the ECW/BCM ratio was calculated. The patients were divided into four groups based on the quartile of ECW/BCM ratio. Multivariate logistic regression analysis and subgroup analysis were conducted. Results: A total of 3 160 patients were included in the final analysis, of which 761 (24.1%) developed CI. There were 1 868 males (59.1%) and 1 292 females (40.9%), and the mean age was (55±15) years. Multivariate logistic regression analysis showed that the risk of CI in ECW/BCM Q3 group was 1.55 times (95%CI: 1.03-2.34, P=0.035) of that in group Q1, while the risk of CI in Q4 group was 1.62 times of that in group Q1 (95%CI: 1.05-2.51, P=0.029). Subgroup analysis showed that there was an interaction between previous cerebrovascular event and ECW/BCM on CI (P for interaction=0.04). Patients with a previous history of cerebrovascular events had a higher risk of CI than those without. Among those with no previous cerebrovascular events, the risk of CI in group Q4 was 1.62 times of that in group Q1 (95%CI: 1.19-2.20), while the risk of CI in group Q4 was 7.17 times of that in group Q1 (95%CI: 1.59-32.35) in those with previous cerebrovascular events. Conclusion: Increased ECW/BCM ratio is associated with increased CI risk in patients with MHD, and the risk was more obvious in those with previous history of cerebrovascular events.
Collapse
Affiliation(s)
- Y Z Peng
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | - D Shuai
- Department of Nephrology, the First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang 550002, China
| | - C M Zhou
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | - J Yuan
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | - Y Zha
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| |
Collapse
|
11
|
Ye Z, Saraf A, Ravipati Y, Hoebers F, Catalano PJ, Zha Y, Zapaishchykova A, Likitlersuang J, Guthier C, Tishler RB, Schoenfeld JD, Margalit DN, Haddad RI, Mak RH, Naser M, Wahid KA, Sahlsten J, Jaskari J, Kaski K, Mäkitie AA, Fuller CD, Aerts HJWL, Kann BH. Development and Validation of an Automated Image-Based Deep Learning Platform for Sarcopenia Assessment in Head and Neck Cancer. JAMA Netw Open 2023; 6:e2328280. [PMID: 37561460 PMCID: PMC10415962 DOI: 10.1001/jamanetworkopen.2023.28280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/12/2023] [Accepted: 06/27/2023] [Indexed: 08/11/2023] Open
Abstract
Importance Sarcopenia is an established prognostic factor in patients with head and neck squamous cell carcinoma (HNSCC); the quantification of sarcopenia assessed by imaging is typically achieved through the skeletal muscle index (SMI), which can be derived from cervical skeletal muscle segmentation and cross-sectional area. However, manual muscle segmentation is labor intensive, prone to interobserver variability, and impractical for large-scale clinical use. Objective To develop and externally validate a fully automated image-based deep learning platform for cervical vertebral muscle segmentation and SMI calculation and evaluate associations with survival and treatment toxicity outcomes. Design, Setting, and Participants For this prognostic study, a model development data set was curated from publicly available and deidentified data from patients with HNSCC treated at MD Anderson Cancer Center between January 1, 2003, and December 31, 2013. A total of 899 patients undergoing primary radiation for HNSCC with abdominal computed tomography scans and complete clinical information were selected. An external validation data set was retrospectively collected from patients undergoing primary radiation therapy between January 1, 1996, and December 31, 2013, at Brigham and Women's Hospital. The data analysis was performed between May 1, 2022, and March 31, 2023. Exposure C3 vertebral skeletal muscle segmentation during radiation therapy for HNSCC. Main Outcomes and Measures Overall survival and treatment toxicity outcomes of HNSCC. Results The total patient cohort comprised 899 patients with HNSCC (median [range] age, 58 [24-90] years; 140 female [15.6%] and 755 male [84.0%]). Dice similarity coefficients for the validation set (n = 96) and internal test set (n = 48) were 0.90 (95% CI, 0.90-0.91) and 0.90 (95% CI, 0.89-0.91), respectively, with a mean 96.2% acceptable rate between 2 reviewers on external clinical testing (n = 377). Estimated cross-sectional area and SMI values were associated with manually annotated values (Pearson r = 0.99; P < .001) across data sets. On multivariable Cox proportional hazards regression, SMI-derived sarcopenia was associated with worse overall survival (hazard ratio, 2.05; 95% CI, 1.04-4.04; P = .04) and longer feeding tube duration (median [range], 162 [6-1477] vs 134 [15-1255] days; hazard ratio, 0.66; 95% CI, 0.48-0.89; P = .006) than no sarcopenia. Conclusions and Relevance This prognostic study's findings show external validation of a fully automated deep learning pipeline to accurately measure sarcopenia in HNSCC and an association with important disease outcomes. The pipeline could enable the integration of sarcopenia assessment into clinical decision making for individuals with HNSCC.
Collapse
Affiliation(s)
- Zezhong Ye
- Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Massachusetts
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
| | - Anurag Saraf
- Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Massachusetts
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
| | - Yashwanth Ravipati
- Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Massachusetts
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
| | - Frank Hoebers
- Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Massachusetts
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
- Department of Radiation Oncology (Maastro), GROW School for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, the Netherlands
| | - Paul J. Catalano
- Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts
- Department of Data Science, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
| | - Yining Zha
- Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Massachusetts
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
| | - Anna Zapaishchykova
- Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Massachusetts
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
- Radiology and Nuclear Medicine, CARIM and GROW, Maastricht University, Maastricht, the Netherlands
| | - Jirapat Likitlersuang
- Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Massachusetts
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
| | - Christian Guthier
- Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Massachusetts
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
| | - Roy B. Tishler
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
| | - Jonathan D. Schoenfeld
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
| | - Danielle N. Margalit
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
| | - Robert I. Haddad
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
| | - Raymond H. Mak
- Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Massachusetts
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
| | - Mohamed Naser
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Kareem A. Wahid
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Jaakko Sahlsten
- Department of Computer Science, Aalto University School of Science, Espoo, Finland
| | - Joel Jaskari
- Department of Computer Science, Aalto University School of Science, Espoo, Finland
| | - Kimmo Kaski
- Department of Computer Science, Aalto University School of Science, Espoo, Finland
| | - Antti A. Mäkitie
- Department Otorhinolaryngology–Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland
| | - Clifton D. Fuller
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Hugo J. W. L. Aerts
- Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Massachusetts
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
- Radiology and Nuclear Medicine, CARIM and GROW, Maastricht University, Maastricht, the Netherlands
- Department of Radiology, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
| | - Benjamin H. Kann
- Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Massachusetts
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
| |
Collapse
|
12
|
Ye Z, Saraf A, Ravipati Y, Hoebers F, Zha Y, Zapaishchykova A, Likitlersuang J, Tishler RB, Schoenfeld JD, Margalit DN, Haddad RI, Mak RH, Naser M, Wahid KA, Sahlsten J, Jaskari J, Kaski K, Mäkitie AA, Fuller CD, Aerts HJ, Kann BH. Fully-automated sarcopenia assessment in head and neck cancer: development and external validation of a deep learning pipeline. medRxiv 2023:2023.03.01.23286638. [PMID: 36945519 PMCID: PMC10029039 DOI: 10.1101/2023.03.01.23286638] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 06/18/2023]
Abstract
Purpose Sarcopenia is an established prognostic factor in patients diagnosed with head and neck squamous cell carcinoma (HNSCC). The quantification of sarcopenia assessed by imaging is typically achieved through the skeletal muscle index (SMI), which can be derived from cervical neck skeletal muscle (SM) segmentation and cross-sectional area. However, manual SM segmentation is labor-intensive, prone to inter-observer variability, and impractical for large-scale clinical use. To overcome this challenge, we have developed and externally validated a fully-automated image-based deep learning (DL) platform for cervical vertebral SM segmentation and SMI calculation, and evaluated the relevance of this with survival and toxicity outcomes. Materials and Methods 899 patients diagnosed as having HNSCC with CT scans from multiple institutes were included, with 335 cases utilized for training, 96 for validation, 48 for internal testing and 393 for external testing. Ground truth single-slice segmentations of SM at the C3 vertebra level were manually generated by experienced radiation oncologists. To develop an efficient method of segmenting the SM, a multi-stage DL pipeline was implemented, consisting of a 2D convolutional neural network (CNN) to select the middle slice of C3 section and a 2D U-Net to segment SM areas. The model performance was evaluated using the Dice Similarity Coefficient (DSC) as the primary metric for the internal test set, and for the external test set the quality of automated segmentation was assessed manually by two experienced radiation oncologists. The L3 skeletal muscle area (SMA) and SMI were then calculated from the C3 cross sectional area (CSA) of the auto-segmented SM. Finally, established SMI cut-offs were used to perform further analyses to assess the correlation with survival and toxicity endpoints in the external institution with univariable and multivariable Cox regression. Results DSCs for validation set (n = 96) and internal test set (n = 48) were 0.90 (95% CI: 0.90 - 0.91) and 0.90 (95% CI: 0.89 - 0.91), respectively. The predicted CSA is highly correlated with the ground-truth CSA in both validation (r = 0.99, p < 0.0001) and test sets (r = 0.96, p < 0.0001). In the external test set (n = 377), 96.2% of the SM segmentations were deemed acceptable by consensus expert review. Predicted SMA and SMI values were highly correlated with the ground-truth values, with Pearson r β 0.99 (p < 0.0001) for both the female and male patients in all datasets. Sarcopenia was associated with worse OS (HR 2.05 [95% CI 1.04 - 4.04], p = 0.04) and longer PEG tube duration (median 162 days vs. 134 days, HR 1.51 [95% CI 1.12 - 2.08], p = 0.006 in multivariate analysis. Conclusion We developed and externally validated a fully-automated platform that strongly correlates with imaging-assessed sarcopenia in patients with H&N cancer that correlates with survival and toxicity outcomes. This study constitutes a significant stride towards the integration of sarcopenia assessment into decision-making for individuals diagnosed with HNSCC. SUMMARY STATEMENT In this study, we developed and externally validated a deep learning model to investigate the impact of sarcopenia, defined as the loss of skeletal muscle mass, on patients with head and neck squamous cell carcinoma (HNSCC) undergoing radiotherapy. We demonstrated an efficient, fullyautomated deep learning pipeline that can accurately segment C3 skeletal muscle area, calculate cross-sectional area, and derive a skeletal muscle index to diagnose sarcopenia from a standard of care CT scan. In multi-institutional data, we found that pre-treatment sarcopenia was associated with significantly reduced overall survival and an increased risk of adverse events. Given the increased vulnerability of patients with HNSCC, the assessment of sarcopenia prior to radiotherapy may aid in informed treatment decision-making and serve as a predictive marker for the necessity of early supportive measures.
Collapse
Affiliation(s)
- Zezhong Ye
- Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, United States
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States
| | - Anurag Saraf
- Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, United States
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States
| | - Yashwanth Ravipati
- Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, United States
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States
| | - Frank Hoebers
- Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, United States
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States
- Department of Radiation Oncology (Maastro), GROW School for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, the Netherlands
| | - Yining Zha
- Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, United States
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States
| | - Anna Zapaishchykova
- Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, United States
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States
- Department of Radiology, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States
| | - Jirapat Likitlersuang
- Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, United States
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States
| | - Roy B. Tishler
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States
| | - Jonathan D. Schoenfeld
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States
| | - Danielle N. Margalit
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States
| | - Robert I. Haddad
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States
| | - Raymond H. Mak
- Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, United States
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States
| | - Mohamed Naser
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States
| | - Kareem A. Wahid
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States
| | - Jaakko Sahlsten
- Department of Computer Science, Aalto University School of Science, Espoo, Finland
| | - Joel Jaskari
- Department of Computer Science, Aalto University School of Science, Espoo, Finland
| | - Kimmo Kaski
- Department of Computer Science, Aalto University School of Science, Espoo, Finland
| | - Antti A. Mäkitie
- Department Otorhinolaryngology – Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland
| | - Clifton D. Fuller
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States
| | - Hugo J.W.L. Aerts
- Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, United States
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States
- Department Otorhinolaryngology – Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland
- Department of Radiology, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States
| | - Benjamin H. Kann
- Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, United States
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States
| |
Collapse
|
13
|
Da JJ, Sun Y, Chen JC, Li Q, Yang YQ, He S, Yang NY, He PH, Hu Y, Long YJ, Yuan J, Zha Y. [Effect of hemoperfusion on protein energy wasting and long-term prognosis in patients on maintenance hemodialysis]. Zhonghua Yi Xue Za Zhi 2023; 103:559-565. [PMID: 36822866 DOI: 10.3760/cma.j.cn112137-20220925-02022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
Objective: To explore the effect of hemoperfusion (HP) combined with hemodialysis (HD) (HD+HP) on protein energy wasting (PEW) and long-term prognosis in patients on maintenance HD (MHD). Methods: A prospective multicenter cohort study was conducted. Adult MHD patients who completed PEW assessment and underwent regular dialysis between July 2015 and July 2021 at 23 hemodialysis centers in Guizhou Province were selected. Demographic characteristics, physical indicators, laboratory indicators, 3-day diet diary and HP treatment data of the subjects were collected. The patients were divided into different groups according to the presence or absence of HP, the frequency of HP treatment and the type of cartridge, and then relevant indicators were compared. Multivariate logistic regression model and Cox proportional regression model were used to analyze the influence of HP treatment on PEW risk in MHD patients. Meanwhile, Kaplan-Meier method was used to plot the survival curve. Results: A total of 4 623 MHD patients (2 789 males and 1 834 females) aged (53.7±15.9) years were included in the study, with a median dialysis age of 64.3 (44.3, 92.3) months. There were 3 429 (74.2%) MHD patients treated with HD+HP, and 1 194 patients (25.8%) were not treated with HP. According to the 2008 diagnostic criteria of the International Society for Renal Nutrition and Metabolism (ISRNM), the incidence of PEW was 26.0% (1 204/4 623). Multivariate logistic regression analysis showed that female (OR=2.48, 95%CI: 1.55-3.95, P<0.001), diabetes (OR=1.75, 95%CI: 1.08-2.83, P=0.024) and high-sensitivity C-reactive protein (hs-CRP) (OR=1.02, 95%CI: 1.01-1.03, P=0.003) were risk factors for PEW, while treatment with HD+HP (OR=0.51, 95%CI: 0.31-0.87, P=0.012) and elevated triglyceride levels (OR=0.62, 95%CI: 0.48-0.80, P<0.001) were protective factors. Cox hazard ratio regression showed that among different HP treatment frequencies and cartridge types, 2 times/month (HR=0.40, 95%CI: 0.17-0.95, P=0.037), 3 times/month (HR=0.44, 95%CI: 0.23-0.85, P=0.014), 4 times/month (HR=0.54, 95%CI: 0.34-0.85, P=0.008), HA130 (HR=0.57, 95%CI: 0.36-0.89, P=0.014) and HA230 (HR=0.30, 95%CI: 0.15-0.63, P=0.001) had protective effects on the occurrence of PEW in MHD patients. The all-cause mortality rate was 11.3% (521/4 623) at 33 (24, 48) months of follow-up. Kaplan-Meier analysis showed that patients undergoing 4 times/month HP treatment (χ2=36.78, P<0.001) and using HA230 (χ2=9.46, P=0.002) had the highest survival rate. Conclusion: Treatment with HD+HP is a protective factor for PEW in patients with MHD, and 4 times/month HP treatment or HA230 significantly reduces the risk of PEW and all-cause mortality in patients with MHD.
Collapse
Affiliation(s)
- J J Da
- Department of Nephrology, Guizhou Provincial People's Hospital, NHC Key Laboratory of Pulmonary Immunological Diseases, Guiyang 550002, China
| | - Y Sun
- Department of Nephrology, General Hospital of Shougang Shuicheng Iron & Steel (Group) Co. Ltd, Liupanshui 553000, China
| | - J C Chen
- Department of Nephrology, General Hospital of Guizhou Water Mine Holding Group Co. Ltd, Liupanshui 553000, China
| | - Q Li
- Department of Nephrology, Guizhou Provincial People's Hospital, NHC Key Laboratory of Pulmonary Immunological Diseases, Guiyang 550002, China
| | - Y Q Yang
- Department of Nephrology, Guizhou Provincial People's Hospital, NHC Key Laboratory of Pulmonary Immunological Diseases, Guiyang 550002, China
| | - S He
- Department of Nephrology, Guizhou Provincial People's Hospital, NHC Key Laboratory of Pulmonary Immunological Diseases, Guiyang 550002, China
| | - N Y Yang
- Department of Nephrology, Guizhou Provincial People's Hospital, NHC Key Laboratory of Pulmonary Immunological Diseases, Guiyang 550002, China
| | - P H He
- Department of Nephrology, Guizhou Provincial People's Hospital, NHC Key Laboratory of Pulmonary Immunological Diseases, Guiyang 550002, China
| | - Y Hu
- Department of Nephrology, Guizhou Provincial People's Hospital, NHC Key Laboratory of Pulmonary Immunological Diseases, Guiyang 550002, China
| | - Y J Long
- Department of Nephrology, Guizhou Provincial People's Hospital, NHC Key Laboratory of Pulmonary Immunological Diseases, Guiyang 550002, China
| | - J Yuan
- Department of Nephrology, Guizhou Provincial People's Hospital, NHC Key Laboratory of Pulmonary Immunological Diseases, Guiyang 550002, China
| | - Y Zha
- Department of Nephrology, Guizhou Provincial People's Hospital, NHC Key Laboratory of Pulmonary Immunological Diseases, Guiyang 550002, China
| |
Collapse
|
14
|
Dai L, Tian ML, Zha Y, Liu L, Li ZS, Huang CC, Yuan J. [Association of lean tissue index with arteriovenous fistula dysfunction in maintenance hemodialysis patients]. Zhonghua Gan Zang Bing Za Zhi 2023; 39:32-35. [PMID: 36776012 DOI: 10.3760/cma.j.cn441217-20220621-00633] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Abstract
The clinical data of maintenance hemodialysis (MHD) patients from twenty hemodialysis centers in Guizhou province from June to September 2020 were collected by cross-sectional study. The patients were divided into AFD group and non-AFD group according to whether AFD had occurred. LTI was measured by body composition monitor. The results showed that the incidence of AFD in 2 781 MHD patients was 30.0% (835/2 781). Median LTI level was 15.2 (13.2, 17.5) kg/m2. The LTI level in the AFD group was higher than that in the non-AFD group (P < 0.05). According to the tertiles of LTI, low LTI group (LTI ≤ 13.9 kg/m2) had the highest incidence of AFD (35.5%, 334/940), and the high LTI group had the lowest incidence of AFD (26.3%, 241/916), and the difference among the three groups was statistically significant (χ2=20.182,P < 0.001). Multivariate logistic regression analysis showed that low LTI group as the reference, the risk of AFD in moderate LTI group (13.9 kg/m2 < LTI ≤ 16.6 kg/m2) and high LTI group were associated with the 20.0% (OR=0.800, 95% CI 0.650-0.986, P=0.036) and 22.8% (OR=0.772, 95% CI 0.616-0.966, P=0.024) decrease, respectively. These results suggest that low LTI level is independently associated with an increased risk of AFD in MHD patients.
Collapse
Affiliation(s)
- L Dai
- Department of Nephrology, the Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang 550001, China
| | - M L Tian
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | - Y Zha
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | - L Liu
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | - Z S Li
- Department of Nephrology, the Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang 550001, China
| | - C C Huang
- Graduate School of Guizhou University of Traditional Chinese Medicine, Guiyang 550002, China Dai Lu and Tian Maolu contributed equally to this study
| | - J Yuan
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, China Key Laboratory of Diagnosis and Treatment of Pulmonary Immune Diseases, NHC, Guiyang 550002, China
| |
Collapse
|
15
|
Yang YQ, Yuan J, Liu L, Qie SW, Yang L, Zha Y. [Interactive effect of hypoparathyroidism and type 2 diabetes mellitus on peritoneal dialysis related peritonitis]. Zhonghua Yi Xue Za Zhi 2022; 102:864-869. [PMID: 35330580 DOI: 10.3760/cma.j.cn112137-20210928-02177] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Objective: To investigate the interactive effect of hypoparathyroidism (HPTH) and type 2 diabetes mellitus (T2DM) on peritonitis in patients on peritoneal dialysis (PD). Methods: In this retrospective cohort study, all PD patients who were firstly catheterized in the peritoneal dialysis center of Guizhou Provincial People's Hospital from January 1, 2012 to December 31, 2018 were included. The characteristics of demographics, baseline clinical and laboratory data were collected, and patients were followed up until December 31, 2020. Kaplan-Meier survival curve and Cox regression analysis were used to explore the associations between the interaction of HPTH+T2DM and peritonitis. Results: A total of 270 PD patients were enrolled in this study, aged (39.9±13.2) years, including 143 males and 24 T2DM patients. These serum levels of intact parathyroid hormone (iPTH) [M(Q1, Q3)] was 268.1 (121.7, 447.0)pg/ml. After a median follow-up of 29.5 (range from 4.0 to 75.0) months, peritonitis occurred in 69 (25.6%) PD patients for the first time. After controlling for confounding factors, the interaction analysis showed that the risk of peritonitis in T2DM patients with HPTH (n=12) was 3.48 times that of non-T2DM patients without HPTH (n=180) (HR=3.48, 95%CI: 1.04-3.87, P=0.034), which was also greater than the sum of the factors alone (HR=1.35, 95%CI: 0.78-2.31 and HR=0.82, 95%CI: 0.20-3.40). The synergy index between HPTH and T2DM was 1.95, the attributable proportion of interaction was 67.6%, and the relative excess risk of interaction was 2.35. The receiver operating characteristic (ROC) curve indicated that the area under the curve of combined diagnosis of HPTH and T2DM was 0.626 (95%CI: 0.550-0.703, P=0.039). Conclusion: The positive interaction between HPTH and T2DM is an independent risk factor for peritonitis in PD patients, both of which can significantly increase the risk of peritonitis.
Collapse
Affiliation(s)
- Y Q Yang
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | - J Yuan
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | - L Liu
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | - S W Qie
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | - L Yang
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | - Y Zha
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| |
Collapse
|
16
|
DA J, Dong R, Li Q, Yu J, Zha Y. POS-190 Relationship of hypothalamic inflammation and protein energy wasting in Patients with Maintenance Hemodialysis. Kidney Int Rep 2022. [DOI: 10.1016/j.ekir.2022.01.206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
17
|
LIU S, Da J, Yu J, Dong R, Zha Y. POS-341 Leptin attenuates lipid deposition by up-regulating insulin induced gene 1 in palmitic acid-induced renal tubular epithelial cells. Kidney Int Rep 2022. [DOI: 10.1016/j.ekir.2022.01.362] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
18
|
Yu J, Mao Y, Zha Y. POS-355 IMMUNE REGULATION OF HMGN1 BY TARGETING TLR4 SIGNAL PATHWAY IN DIABETIC NEPHROPATHY. Kidney Int Rep 2022. [DOI: 10.1016/j.ekir.2022.01.376] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
19
|
Han JB, Wang WQ, Zhu ZZ, Wang L, Wang XW, Zha Y, Lyu W. [Research progress of nasal mucosal epithelial cells in chronic rhinosinusitis]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2022; 57:78-81. [PMID: 35090218 DOI: 10.3760/cma.j.cn115330-20210303-00103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Affiliation(s)
- J B Han
- Department of Otorhinolaryngology Head and Neck Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
| | - W Q Wang
- Department of Otorhinolaryngology Head and Neck Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
| | - Z Z Zhu
- Department of Otorhinolaryngology Head and Neck Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
| | - L Wang
- Department of Otorhinolaryngology Head and Neck Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
| | - X W Wang
- Department of Otorhinolaryngology Head and Neck Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
| | - Y Zha
- Department of Otorhinolaryngology Head and Neck Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
| | - W Lyu
- Department of Otorhinolaryngology Head and Neck Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
| |
Collapse
|
20
|
Shui L, Da JJ, He PH, Li Q, Ou QQ, Zha Y. [Relationship between platelet/lymphocyte ratio and cognitive impairment in diabetic patients treated with maintenance hemodialysis]. Zhonghua Yi Xue Za Zhi 2021; 101:722-726. [PMID: 33721951 DOI: 10.3760/cma.j.cn112137-20201202-03244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To explore the relationship between platelet/lymphocyte ratio (PLR) and cognitive impairment (CI) in diabetic patients treated with maintenance hemodialysis (MHD). Methods: The data of age, gender, underlying diseases, medication history, mini-mental state examination (MMSE) and biochemical indexes of diabetic MHD patients who were treated in 18 hemodialysis center in Guizhou Province between May and August 2019 were collected. According to whether they had CI or not, the patients were divided into CI group and control group, and the clinical characteristics between the two groups were compared. In addition, the patients were divided into four groups according to the quartile of PLR (PLR Q1, Q2, Q3 and Q4 group). Multivariate logistic regression models were used to analyze the relationship between PLR level and CI in diabetic MHD patients. The receiver operating characteristic (ROC) curve was used to evaluate the diagnostic value of PLR in detecting CI in diabetic MHD patients. Results: Totally, 586 diabetic MHD patients (389 males) were included, with a mean age of (63±11) years. Multivariate logistic regression analysis showed that PLR was associated with the risk of CI in diabetic MHD patients, and the risk of CI in PLR Q4 group was 3.022 times of that of PLR Q1 Group (95%CI: 1.866-4.895, P<0.001). After adjusting for gender, age, dialysis age and education level, the risk of CI in PLR Q4 group was 2.529 times of that in PLR Q1 Group (95%CI: 1.536-4.164, P<0.001). After further adjusting for hemoglobin, albumin, creatinine, leukocyte and blood glucose, the risk of CI in PLR Q4 group was 2.281 times of that in PLR Q1 group (95%CI: 1.203-4.326, P=0.012). ROC curve analysis showed that the optimal threshold for PLR to predict CI in diabetic MHD patients was 155.3, with a sensitivity of 57.2% and a specificity of 60.8%, and the area under the curve was 0.608 (95%CI: 0.561-0.644, P<0.001). Conclusion: PLR is associated with CI in diabetic MHD patients.
Collapse
Affiliation(s)
- L Shui
- Zunyi Medical University, Zunyi 563000, China
| | - J J Da
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | - P H He
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | - Q Li
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | - Q Q Ou
- Zunyi Medical University, Zunyi 563000, China
| | - Y Zha
- Zunyi Medical University, Zunyi 563000, China
| |
Collapse
|
21
|
Hatogai K, Kim D, Zha Y, Steinberg G, Pearson AT, Gajewski TF, Sweis RF. Multiplex immunofluorescence to assess the tumor microenvironment in bladder cancer. Urol Oncol 2020. [DOI: 10.1016/j.urolonc.2020.10.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
22
|
Zhu Z, Wang W, Zhang X, Wang X, Zha Y, Chen Y, Zhou L, Lv W. Nasal fluid cytology and cytokine profiles of eosinophilic and non-eosinophilic chronic rhinosinusitis with nasal polyps. Rhinology 2020; 58:314-322. [PMID: 32251491 DOI: 10.4193/rhin19.275] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous disease with different clinical characteristics and different treatment responsiveness. The aims of this study were to compare the nasal fluid cytology and cytokines between eosinophilic CRSwNP (eCRSwNP) and non-eosinophilic CRSwNP (neCRSwNP) and establish a new multivariate model to predict eCRSwNP before surgery to improve personalized treatment for CRSwNP patients. METHODS Eighty-six consecutive patients with CRSwNP and sixteen healthy controls were recruited in this study. Nasal fluid (NF) was collected from all subjects and nasal polyp tissue was collected during the surgery. The differential cell counts and concentrations of IL-6, IL-8, TNF-77; and IL-10 in NF were measured. Univariate and multivariate logistic regression were used to identify predictors for eCRSwNP. RESULTS There were more inflammatory cells in NF of CRSwNP than controls. The eosinophil percentage was significantly higher in eCRSwNP than neCRSwNP and controls. The level of IL-8 was significantly higher in neCRSwNP than in eCRSwNP and controls. Blood eosinophilia, nasal fluid eosinophilia, higher total ethmoid score / total maxillary score (E/M ratio) and higher visual analogue scale (VAS) score of CRS were associated with eCRSwNP, the area under receiver operating characteristic curve (AUC) was 0.800, 0.755, 0.703 and 0.648, respectively. Using the coefficients of multivariate regression, we set up a scoring system to predict eCRSwNP with three of the variates and the AUC was 0.883. CONCLUSION ECRSwNP, neCRSwNP and healthy controls demonstrated different cytology and cytokine profiles in NF. A new preoperational multivariate prediction model for eCRSwNP with NF eosinophilia, blood eosinophilia and higher E/M ratio was established.
Collapse
Affiliation(s)
- Z Zhu
- Department of Otolaryngology-Head and Neck Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
| | - W Wang
- Department of Otolaryngology-Head and Neck Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
| | - X Zhang
- Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
| | - X Wang
- Department of Otolaryngology-Head and Neck Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
| | - Y Zha
- Department of Otolaryngology-Head and Neck Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
| | - Y Chen
- Department of Otolaryngology-Head and Neck Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
| | - L Zhou
- Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
| | - W Lv
- Department of Otolaryngology-Head and Neck Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
| |
Collapse
|
23
|
Onderdonk B, Luke J, Bhave S, Karrison T, Chang P, Zha Y, Carll T, Krausz T, Huang L, Janisch L, Hseu R, Khodarev N, Weichselbaum R, Pitroda S, Chmura S. Multi-Site SBRT and Sequential Pembrolizumab: Treated Metastasis Control and Immune-Related Expression Predict Outcomes. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.05.046] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
24
|
Tian ML, Song WL, Li Q, Shen Y, Hu Y, Yuan J, Zha Y. [Association of low serum indirect bilirubin level with all-cause mortality in maintenance hemodialysis patients]. Zhonghua Yi Xue Za Zhi 2019; 99:2203-2207. [PMID: 31434393 DOI: 10.3760/cma.j.issn.0376-2491.2019.28.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
Objective: To investigate the association of low serum indirect bilirubin (IBIL) level with all-cause mortality in maintenance hemodialysis (MHD) patients. Methods: A multicenter retrospective cohort study was conducted in seven hemodialysis centers of Guizhou province. The adult outpatients who underwent hemodialysis for more than 3 months were included between June 2015 and June 2016. Demographics, baseline clinical and laboratory test results were collected. Patients were divided into 4 groups according to their baseline serum IBIL levels (interquartile range), and followed up until June 30, 2018. Kaplan-Meier method was used to compare the survival rate of each group. Cox regression model was used to analyze the association of IBIL with all-cause mortality. Results: A total of 885 hemodialysis dialysis patients with baseline IBIL data were enrolled in this study, with age of (55.4±16.2) years old, among whom 57.9% (512/885) were male. Median IBIL was 4.8 μmol/L and interquartile range was 3.3-7.0 μmol/L. The comparison between IBIL quartile groups showed that the differences in proportion of diabetics, hemoglobin, serum albumin, platelet, serum calcium, alanine aminotransferase (ALT), uric acid and urea nitrogen were statistically significant (all P<0.05). After a median follow-up of 24 months, 210 patients died, and 96 cases became lost to follow-up. Kaplan-Meier curves showed higher all-cause mortality in patients with IBIL≤3.3 μmol/L (Q1 group) (65/219, P=0.015). After adjusting for age, gender, comorbidities, and biochemical indicators, taking baseline IBIL Q2 level (IBIL 3.4~4.8 μmol/L) as a reference, the hazard ratio for all-cause death in patients with IBIL≤3.3 μmol/L was 1.661 (95%CI: 1.114-2.476, P=0.013). Kaplan-Meier survival curve showed that there was no significant difference in mortality between the quartile groups according to total bilirubin (TBIL) or direct bilirubin (DBIL) (P=0.167, 0.156). Conclusion: Baseline low serum IBIL in maintenance hemodialysis patients is associated with all-cause mortality.
Collapse
Affiliation(s)
- M L Tian
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | - W L Song
- Department of Nephrology, Qiannan People's Hospital, Duyun 558000, Guizhou, China
| | - Q Li
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | - Y Shen
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | - Y Hu
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | - J Yuan
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | - Y Zha
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| |
Collapse
|
25
|
Li Q, Deng KH, Long YJ, Lin X, Qie SW, Zhou CM, Yang X, Zha Y. [Influencing factors of protein energy wasting in maintenance hemodialysis patients]. Zhonghua Yi Xue Za Zhi 2019; 99:1567-1571. [PMID: 31154724 DOI: 10.3760/cma.j.issn.0376-2491.2019.20.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To analyze the influencing factors of protein energy wasting (PEW) in maintenance hemodialysis (MHD) patients. Methods: A multicenter cross-sectional study was conducted in eleven hemodialysis centers of Guizhou province between June and August 2018. Clinical data, physical parameters, body composition data and laboratory values of MHD patients were collected. Analysis of variance was used to assess the impact of the indicators on the prevalence of PEW. Factor analysis was carried out after further classifing the factors into several common factors, and logistic regression was used to analyze the impact of common factors on PEW. Results: The results of univariate analysis showed that somatic cell mass, lean weight, fat content, body mass index (BMI), grip strength, leg circumference, hip circumference, waist circumference, midpoint circumference of upper arm, triceps skin fold thickness, hemoglobin, albumin, prealbumin, serum calcium, phosphorus, serum magnesium, creatinine, parathyroid hormone were the influential factors of PEW (all P<0.05). Factor analysis indicated that the above indicators can be classified into five common factors. Logistic regression model showed that with the increase of the prevalence of PEW, the scores of common factors decreased, the absolute value of regression coefficient beta in sequence, was common factor 2 (β=-2.258, P<0.001), common factor 4 (β=-1.589, P<0.001), common factor 1 (β=-1.144, P=0.001) and common factor 3 (β=-0.740, P=0.016). Conclusion: The reduction of fat content, anemia, hypoproteinemia, disorder of calcium and phosphorus metabolism were important factors influencing PEW.
Collapse
Affiliation(s)
- Q Li
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | - K H Deng
- Department of Nephrology, the Second Affiliated Hospital of Guizhou Medical University, Kaili 556000, Guizhou, China
| | - Y J Long
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | - X Lin
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | - S W Qie
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | - C M Zhou
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | - X Yang
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | - Y Zha
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| |
Collapse
|
26
|
Hu SS, Zhou CM, Li Q, Su FX, Chen S, Da JJ, Zha Y. [Association of platelet/lymphocyte ratio and neutrophil/lymphocyte ratio with protein-energy wasting in maintenance hemodialysis patients]. Zhonghua Yi Xue Za Zhi 2019; 99:587-592. [PMID: 30818927 DOI: 10.3760/cma.j.issn.0376-2491.2019.08.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To explore the association of platelet/lymphocyte ratio (PLR) and neutrophil/lymphocyte ratio (NLR) with protein energy wasting (PEW) in maintenance hemodialysis (MHD) patients. Methods: A multicenter cross-sectional study was conducted in eleven hemodialysis centers of Guizhou province from June to August, 2017. Clinical data, physical parameters, body composition data and laboratory values of MHD patients were collected. PLR and NLR were calculated according to routine blood test. All patients were divided into four groups (Q1-Q4) according to the median and quartile of PLR and NLR. Multivariate logistic regression models were applied to analyze the relationships between PLR, NLR and PEW. The comparison of predictive power of PLR and NLR for PEW was evaluated by receiver operating characteristic curve (ROC). Results: A total of 936 MHD patients were enrolled (519 males, 417 females), with a mean age of (55.6±15.6) years. The prevalence of PEW was 46.2% (432/936). Multivariate logistic regression analysis showed that patients in group PLR Q3 and Q4 were 2.07 (95%CI: 1.03-4.13, P=0.014) and 2.73 (95%CI: 1.58-4.74, P<0.001) times more likely to have PEW, compared with those in group PLR Q1 in unadjusted models. PLR was significantly associated with the development of PEW after adjusting age, sex, history of hypertension, diabetes and hemoglobin. Patients in Group PLR Q3 and Q4 were 2.82 times (95%CI: 1.42-5.60, P=0.003) and 2.93 times (95%CI: 1.50-5.73, P=0.002) times more likely to have PEW than those in Group PLR Q1. The ROC showed that only PLR can predict the development of PEW with a diagnostic threshold of 144.09 [area under curve (AUC)=0.61, 95%CI: 0.56-0.66, P<0.001], with a sensitivity and specificity of 61% and 58%, respectively, while the AUC of NLR is 0.55 (P=0.091). Conclusion: For MHD patients, only PLR could be a relevent factor of PEW and it showed the predictive power of PEW rather than NLR.
Collapse
Affiliation(s)
- S S Hu
- Zunyi Medical University, Zunyi 563000, China
| | - C M Zhou
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | - Q Li
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | - F X Su
- Zunyi Medical University, Zunyi 563000, China
| | - S Chen
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | - J J Da
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | - Y Zha
- Zunyi Medical University, Zunyi 563000, China (is working in the Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, China)
| |
Collapse
|
27
|
Zha Y, Lv W, Gao YL, Zhu ZZ, Gao ZQ. [Design of cross-sectional anatomical model focused on drainage pathways of paranasal sinuses]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2018; 32:683-686. [PMID: 29771086 DOI: 10.13201/j.issn.1001-1781.2018.09.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 01/23/2018] [Indexed: 11/12/2022]
Abstract
Objective:To design and produce cross-sectional anatomical models of paranasal sinuses for the purpose of demonstrating drainage pathways of each nasal sinus for the young doctors. Method:We reconstructed the three-dimensional model of sinuses area based on CT scan data, and divided it into 5 thick cross-sectional anatomy models by 4 coronal plane,which cross middle points of agger nasi cell, ethmoid bulla, posterior ethmoid sinuses and sphenoid sinus respectively. Then a 3D printerwas used to make anatomical cross-sectional anatomical models.Result:Successfully produced a digital 3D printing cross-sectional models of paranasal sinuses. Sinus drainage pathways were observed on the models. Conclusion:The cross-sectional anatomical models made by us can exactly and intuitively demonstrate the ostia of each sinus cell and they can help the young doctors to understand and master the key anatomies and relationships which are important to the endoscopic sinus surgery.
Collapse
Affiliation(s)
- Y Zha
- Department of Otolaryngology-Head and Neck Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China
| | | | | | | | | |
Collapse
|
28
|
Da JJ, Peng HY, Lin X, Shen Y, Zhao JQ, He S, Zha Y. [Resting metabolic rate estimated by bioelectrical impedance analysis and its determinants in maintenance hemodialysis patients]. Zhonghua Yi Xue Za Zhi 2018; 98:912-916. [PMID: 29665664 DOI: 10.3760/cma.j.issn.0376-2491.2018.12.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To explore the level of resting energy expenditure (REE) estimated by bioelectrical impedance analysis and the association of resting metabolic rate (RMR) with clinical related factors, and provide new ideas for improving protein energy wasting (PEW) in maintenance hemodialysis (MHD) patients. Methods: Seven hundred and sixty-five subjects receiving MHD between July 2015 and September 2016 in 11 hemodialysis centers in Guizhou province were enrolled in this cross-sectional study. Bioelectrical impedance analysis was used to measure RMR and body composition, such as lean body mass, fat mass and body cell mass (BCM). Baseline characteristics, routine blood test indexes and biochemical data of hemodialysis patients were collected. The level of RMR and body composition in hemodialysis patients was compared by gender grouping. Then the patients were divided into four groups according to the cutoff value of RMR quartile. Spearman correlation analysis and multiple linear regression analysis were used to analyze the relationships between RMR and clinical related factors. Results: The average age of MHD patients was (54.96±15.78) years and the duriation of dialysis was (42.3±9.0) months. The level of RMR in male patients (474 cases, 61.96%) was significantly higher than that in female patients [1 591(1 444, 1 764) kcal/d vs 1 226 (1 104, 1 354) kcal/d, P<0.001]. However, this significant difference of RMR between different genders disappeared after adjusting for lean body mass (P=0.193). Multiple linear regression analysis showed that RMR was positively correlated with body surface area (β=0.817) and lactate dehydrogenase (LDH) (β=0.198), and negatively correlated with age (β=-0.141), all P<0.05. Conclusion: RMR levels in patients with maintenance hemodialysis are associated with lactate dehydrogenase level, which may become a new index to evaluate energy consumption.
Collapse
Affiliation(s)
- J J Da
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | - H Y Peng
- Renal Division, Department of Nephrology, the Affiliated Baiyun Hospital of Guizhou Medical University, Guiyang 550004, China
| | | | | | | | | | | |
Collapse
|
29
|
He PH, Min YL, Zhou CM, Tong XY, Lin X, Li Q, Zha Y. [Relationship between visceral obesity and atherosclerosis in hemodialysis patients]. Zhonghua Yi Xue Za Zhi 2018; 98:3411-3414. [PMID: 30440135 DOI: 10.3760/cma.j.issn.0376-2491.2018.42.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To evaluate the relationship between surrogate markers of visceral obesity[hypertriglyceridemic waist (HW) phenotype, visceral adiposity index (VAL), lipid accumulation product (LAP)]and atherosclerosis in hemodialysis patients. Methods: A multi-center cross-sectional study was carried out. A total of 961 maintenance hemodialysis (MHD) patients from 11 hemodialysis centers of Guizhou province between July 2016 and September 2017 were enrolled in the study. Anthropometric measures were performed in all subjects. Laboratory parameters including triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein-cholesterol were extracted from the medical records by researchers. Pearson correlation analysis was used to investigate the correlation between HW phenotype, VAI, LAP and plasma atherosclerotic index (AIP). Multivariate linear regression analysis was used to evaluate factors affecting AIP. Results: Totally, 585 men and 376 women aged 18-90 years, with a mean age of (56.08±15.42) years were recruited in the study. Pearson correlation analysis showed that VAI (men: r=0.82, women: r=0.84), LAP (men: r=0.73, women: r=0.74) and having HW phenotype (men: r=0.62, women: r=0.63) correlated positively with AIP (all P<0.001). Multivariate linear regression analysis showed that VAI (men: β=0.77, women: β=0.82) and LAP (men: β=0.73, women: β=0.73) were independent associated factors of AIP after adjustment of BMI, age, smoking and history of diabetes and hypertension (all P<0.001). Conclusions: Surrogate markers of visceral obesity such as having HW phenotype, VAI, LAP correlated positively with AIP. VAI, LAP has positive impacts on AIP independent of BMI, age, smoking and other traditional atherosclerosis risk factors.
Collapse
Affiliation(s)
- P H He
- Renal Division, Department of Medicine, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | - Y L Min
- Department of Nephrology, First People's Hospital of Guiyang, Guiyang 550002, China
| | | | | | | | | | | |
Collapse
|
30
|
Su FX, Wu J, Zhou CM, Li Q, Hu SS, Lin X, Da JJ, Zha Y. [Association of low serum parathyroid hormone with protein-energy wasting in maintenance hemodialysis patients]. Zhonghua Yi Xue Za Zhi 2018; 98:3401-3405. [PMID: 30440133 DOI: 10.3760/cma.j.issn.0376-2491.2018.42.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To examine the relationship between low serum parathyroid hormone (PTH) and protein-energy wasting (PEW) in patients who underwent maintenance hemodialysis (MHD) treatment. Methods: A cross-sectional study was conducted in MHD patients between June 2015 and August 2017 in 11 MHD centers from Guizhou province. Body composition and physical parameters were measured, clinical data and other related laboratory values were collected according to the medical record system. Participants were assigned to low serum PTH group (PTH<150 ng/L), target PTH group (150 ng/L≤ PTH ≤300 ng/L) and high serum PTH group (PTH>300 ng/L). Multivariate logistic regression analysis was used to analyze the relationship between low serum PTH and risk of PEW, which was diagnosed according to the diagnostic criteria recommened by the International Society of Renal Nutrition and Metabolism (ISRNM). Results: A total of 873 MHD patients (488 males and 385 females) were included in the final analysis, with a mean age of 55.0 (44.0, 67.0) years and a mean hemodialysis duration of 31.0(17.0, 54.0) months. In unadjusted model, low serum PTH group was associated with PEW (OR=2.12, 95% CI: 1.26-3.54, P=0.004), when compared with high serum PTH group. After adjustment for age and sex, low serum PTH group was still significantly associated with PEW (OR=2.09, 95% CI: 1.23-3.52, P=0.006). Further adjustment for diabetes and hypertension, the correlation between low serum PTH group and PEW was still significant (OR=2.02, 95% CI: 1.04-3.90, P=0.037). However, the correlation was not observed in target PTH group and high serum PTH group. Conclusion: Low serum PTH was associated with risk of PEW, regardless of age, sex, history of diabetes and hypertension, and thus it might be a promising indicator of PEW in MHD patients.
Collapse
Affiliation(s)
- F X Su
- Department of Nephrology, Affiliated Hospital of Zunyi Medical College, Zunyi 563003, China
| | - J Wu
- Renal Division, Department of Medicine, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | | | | | | | | | | | | |
Collapse
|
31
|
Zha Y, Sun F. [Evaluation of protein-energy wasting in maintenance hemodialysis patients]. Zhonghua Yi Xue Za Zhi 2018; 98:3388-3391. [PMID: 30440132 DOI: 10.3760/cma.j.issn.0376-2491.2018.42.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
|
32
|
Yang L, Zha Y, Feng J, Dong H, Zong C, Lei X, Liang N, Wang X, Gao G, Bai X. Treatment of a Pediatric Case of Severe Hemorrhagic Cystitis: Case Report and Review of Literature. Transplant Proc 2017; 49:2365-2367. [PMID: 29198679 DOI: 10.1016/j.transproceed.2017.10.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2017] [Accepted: 10/04/2017] [Indexed: 11/16/2022]
Abstract
Hemorrhagic cystitis is one of the complications of allogeneic hematopoietic stem cell transplantation. Treatment of hemorrhagic cystitis is difficult, especially in pediatric patients. A pediatric case of severe hemorrhagic cystitis after hematopoietic stem cell transplantation was treated in our hospital with arterial embolization combined with corticosteroid therapy because the conventional therapy was invalid for him. After the treatment, hemorrhagic cystitis was cured. During follow-up, the patient was in stable condition, with normal urine, blood cells returned to normal, bone marrow was in complete remission state, and disease-free survival for more than 8 months. Selective bladder arterial embolism followed by corticosteroid therapy successfully treated the patient.
Collapse
Affiliation(s)
- L Yang
- Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shanxi, China
| | - Y Zha
- Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shanxi, China
| | - J Feng
- Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shanxi, China
| | - H Dong
- Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shanxi, China
| | - C Zong
- Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shanxi, China
| | - X Lei
- Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shanxi, China
| | - N Liang
- Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shanxi, China
| | - X Wang
- Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shanxi, China
| | - G Gao
- Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shanxi, China
| | - X Bai
- Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shanxi, China.
| |
Collapse
|
33
|
Han B, Yang BW, Zhang H, Zha Y, Zhang Y. Effects of axial power shapes on CHF locations in a single tube and in rod bundle assemblies. KERNTECHNIK 2016. [DOI: 10.3139/124.110748] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Abstract
Currently, the prediction of rod bundle CHF is dependent on CHF correlations derived from CHF data. A simple correction factor, such as F-factor, is often used to account for the axial power shape differences based on a simple accumulated energy concept, which has totally no consideration on the impact of true local condition on CHF mechanism. Subsequently, as expected, large uncertainty is often associated with the CHF value and CHF location predictions. For the purpose of obtaining different power shapes effects on CHF, CFD calculated parameter values were used to predict the possible CHF occurrence location. The possible CHF location prediction method proposed in this paper is calculated void fraction, heat transfer coefficient (HTC), liquid temperature distribution and detailed local parameters. And the uniform and non-uniform CHF were analyzed. The prediction of possible CHF locations in a 5 × 5 rod bundle may provide useful information for the design of a full-length CHF test, enhance the accuracy of CHF and CHF location prediction, and reduce the costs of the experimentation.
Collapse
Affiliation(s)
- B. Han
- School of Nuclear Science and Technology , Xi'an Jiaotong University, Xi'an, 710049 , China
| | - B.-W. Yang
- School of Nuclear Science and Technology , Xi'an Jiaotong University, Xi'an, 710049 , China
| | - H. Zhang
- School of Nuclear Science and Technology , Xi'an Jiaotong University, Xi'an, 710049 , China
| | - Y. Zha
- School of Nuclear Science and Technology , Xi'an Jiaotong University, Xi'an, 710049 , China
| | - Y. Zhang
- School of Nuclear Science and Technology , Xi'an Jiaotong University, Xi'an, 710049 , China
| |
Collapse
|
34
|
Han B, Yang BW, Zhang H, Mao H, Zha Y. The effect of spacer grid critical component on pressure drop under both single and two phase flow conditions. KERNTECHNIK 2016. [DOI: 10.3139/124.110745] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Abstract
As pressure drop is one of the most critical thermal hydraulic parameters for spacer grids the accurate estimation of it is the key to the design and development of spacer grids. Most of the available correlations for pressure drop do not contain any real geometrical parameters that characterize the grid effect. The main functions for spacer grid are structural support and flow mixing. Once the boundary sublayer near the rod bundle is disturbed, the liquid forms swirls or flow separation that affect pressure drop. However, under two phase flow conditions, due to the existence of steam bubble, the complexity for spacer grid are multiplied and pressure drop calculation becomes much more challenging. The influence of the dimple location, distance of mixing vane to the nearest strip, and the effect of inter-subchannel mixing among neighboring subchannels on pressure drop and downstream flow fields are analyzed in this paper. Based on this study, more detailed space grid geometry parameters are recommended for adding into the correlation when predicting pressure drop.
Collapse
Affiliation(s)
- B. Han
- Science and Technology Center for Advanced Nuclear Fuel Research , Xi'an Jiaotong University, Xianning West Rd 28, Xi'an, Shaanxi 710049 , P.R. China
| | - B.-W. Yang
- Science and Technology Center for Advanced Nuclear Fuel Research , Xi'an Jiaotong University, Xianning West Rd 28, Xi'an, Shaanxi 710049 , P.R. China
| | - H. Zhang
- Science and Technology Center for Advanced Nuclear Fuel Research , Xi'an Jiaotong University, Xianning West Rd 28, Xi'an, Shaanxi 710049 , P.R. China
| | - H. Mao
- Science and Technology Center for Advanced Nuclear Fuel Research , Xi'an Jiaotong University, Xianning West Rd 28, Xi'an, Shaanxi 710049 , P.R. China
| | - Y. Zha
- Science and Technology Center for Advanced Nuclear Fuel Research , Xi'an Jiaotong University, Xianning West Rd 28, Xi'an, Shaanxi 710049 , P.R. China
| |
Collapse
|
35
|
Liu J, Wu YY, Huang XM, Yang M, Zha BB, Wang F, Zha Y, Sheng L, Chen ZPG, Gu Y. Ageing and type 2 diabetes in an elderly Chinese population: the role of insulin resistance and beta cell dysfunction. Eur Rev Med Pharmacol Sci 2014; 18:1790-1797. [PMID: 24992623] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
OBJECTIVE The aim of this longitudinal study was to examine the effects of ageing on glucose regulation in elderly Chinese men and women. SUBJECTS AND METHODS A total of 4,566 older Chinese men and women (mean age: 70.4 ± 6.7 years) were enrolled in the study. Oral glucose tolerance tests were performed in all participants at baseline and in 3,174 individuals (69.5%) after 3 years of follow-up. Insulin resistance and beta cell function were estimated by the homeostasis model assessment for insulin resistance (HOMA-IR) and beta function (HOMA%-b), respectively. RESULTS At baseline, 1,143 had type 2 diabetes (T2D), 517 had prediabetes and 2,906 had normal glucose tolerance (NGT). After 3 years of follow-up, 769 (42.2%) of 1,821 individuals with NGT at baseline progressed to prediabetes and 153 (8.4%) progressed to T2D. Of individuals with prediabetes at baseline, 17.3% progressed to T2D. In individuals who maintained NGT during follow-up ageing was associated with increased insulin resistance (p ≤ 0.001) and a compensatory increase in beta function (p ≤ 0.001). Individuals with NGT or prediabetes who progressed to T2D during follow-up had a significantly increased insulin resistance and a decreased beta cell function (p < 0.01). In contrast, individuals who regressed from prediabetes to NGT increased both insulin resistance and beta cell function (p < 0.01). CONCLUSIONS Ageing is associated with development of insulin resistance in an Elderly Chinese population. Therefore, maintenance of normal glucose regulation depends on the ability to compensatory increase of the beta cell function.
Collapse
Affiliation(s)
- J Liu
- Department of Endocrinology, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
|
37
|
Le C, Zha Y, Li Y, Sun D, Lu H, Yin B. Eutrophication of lake waters in China: cost, causes, and control. Environ Manage 2010; 45:662-8. [PMID: 20177679 DOI: 10.1007/s00267-010-9440-3] [Citation(s) in RCA: 218] [Impact Index Per Article: 15.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/24/2008] [Accepted: 01/09/2010] [Indexed: 05/23/2023]
Abstract
Lake water eutrophication has become one of the most important factors impeding sustainable economic development in China. Knowledge of the current status of lake water eutrophication and determination of its mechanism are prerequisites to devising a sound solution to the problem. Based on reviewing the literature, this paper elaborates on the evolutional process and current state of shallow inland lake water eutrophication in China. The mechanism of lake water eutrophication is explored from nutrient sources. In light of the identified mechanism strategies are proposed to control and tackle lake water eutrophication. This review reveals that water eutrophication in most lakes was initiated in the 1980s when the national economy underwent rapid development. At present, the problem of water eutrophication is still serious, with frequent occurrence of damaging algal blooms, which have disrupted the normal supply of drinking water in shore cities. Each destructive bloom caused a direct economic loss valued at billions of yuan. Nonpoint pollution sources, namely, waste discharge from agricultural fields and nutrients released from floor deposits, are identified as the two major sources of nitrogen and phosphorus. Therefore, all control and rehabilitation measures of lake water eutrophication should target these nutrient sources. Biological measures are recommended to rehabilitate eutrophied lake waters and restore the lake ecosystem in order to bring the problem under control.
Collapse
Affiliation(s)
- C Le
- Key Laboratory of Virtual Geographic Environment, Ministry of Education, College of Geographic Science, Nanjing Normal University, Nanjing, 210046, People's Republic of China.
| | | | | | | | | | | |
Collapse
|
38
|
Huang Z, Richards MA, Zha Y, Francis R, Lozano R, Ruan J. Determination of inorganic pharmaceutical counterions using hydrophilic interaction chromatography coupled with a Corona CAD detector. J Pharm Biomed Anal 2009; 50:809-14. [PMID: 19616396 DOI: 10.1016/j.jpba.2009.06.039] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2009] [Revised: 06/18/2009] [Accepted: 06/19/2009] [Indexed: 12/01/2022]
Abstract
A simple generic approach was investigated for the determination of inorganic pharmaceutical counterions in drug substances using conventional high performance liquid chromatographic (HPLC) instruments. An intuitive approach combined Corona charged aerosol detection (CAD) with a polymer-based zwitterionic stationary phase in the hydrophilic interaction chromatography (HILIC) mode. Two generic methods based on this HILIC/CAD technique were developed to quantitate counterions such as Cl-, Br-, SO(4)(2-), K+, Ca2+ and Mg2+ in different pharmaceutical compounds. The development and capability of this HILIC/CAD technique analysis were examined. HILIC/CAD was compared to ion chromatography (IC), the most commonly used methodology for pharmaceutical counterion analysis. HILIC/CAD was found to have significant advantages in terms of: (1) being able to quantitate both anions and cations simultaneously without a need to change column/eluent or detection mode; (2) imposing much less restriction on the allowable organic percentage of the eluents than IC, and therefore being more appropriate for analysis of counterions of poorly water-soluble drugs; (3) requiring minimal training of the operating analysts. The precision and accuracy of counterion analysis using HILIC/CAD was not compromised. A typical precision of <2.0% was observed for all tested inorganic counterions; the determinations were within 2.0% relative to the theoretical counterion amount in the drug substance. Additionally, better accuracy was shown for Cl- in several drug substances as compared to IC. The main drawback of HILIC/CAD is its unsuitability for many of the current silica-based HILIC columns, because slight dissolution of silica leads to high baseline noise in the CAD detector. As a result of the universal detection characteristics of Corona CAD and the unique separation capabilities of a zwitterionic stationary phase, an intuitive and robust HPLC method was developed for the generic determination of various counterions in different drug substances. HILIC/CAD technique is a useful alternative methodology, particularly for determination of counterions in low-solubility drugs.
Collapse
Affiliation(s)
- Z Huang
- Bristol-Myers Squibb, Research and Development, 1 Squibb Drive, New Brunswick, NJ 08901, USA.
| | | | | | | | | | | |
Collapse
|
39
|
Abstract
9002 Background: Emerging data suggests that features of the melanoma tumor microenvironment may determine the clinical outcome to immunotherapies. We recently have observed a gene expression signature that correlated with a favorable clinical outcome in response to an IL-12-based melanoma vaccine. Increased expression of chemokine genes and T cell transcripts, and decreased expression of genes associated with aggressive tumor biology, were observed in the favorable group. To determine whether these patterns were reproducible, gene expression profiling was performed from an independent vaccine clinical trial. Methods: Patients with advanced melanoma were treated with autologous, mature monocyte-derived dendritic cells loaded with a combination of melanoma antigen peptides. Pretreatment biopsies were cryopreserved for RNA extraction and gene expression profiling. Patients were categorized into “long survival” (> 24 months) or “short survival” outcomes. Supervised hierarchical clustering was performed to identify genes differentially expressed in the two outcome groups. Results: RNA that passed quality control was obtained from 17 stage IV patients, 5 with a short survival and 12 with a long survival. 408 genes were differentially at least 2- fold. Consistent with previous observations, tumors from favorable outcome patients expressed higher levels of several T cell-specific genes, including Thy1 and CD28; chemokines, including CCL19, CXCL12, and CXCL14; and other immune genes, including LTβ, IL-1R, IFNαR2, IL27R, CD69, and FcRs. Conversely, tumors from unfavorable outcome patients expressed higher levels of pro- angiogeneic genes, including Flt1; anti-apoptotic genes, including SerpinH1 and Serpine1; and multiple collagens. Conclusions: Our results confirm that a subset of transcripts expressed in melanoma metastases may be useful as a predictive biomarker for response to melanoma vaccines. The categories of genes identified point toward new opportunities for overcoming resistance mechanisms. Future studies should integrate gene expression profiling of pre-treatment biopsies as a stratification or enrichment factor in immunotherapy trials. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- T. Gajewski
- University of Chicago, Chicago, IL; University Hospital of Erlangen, Erlangen, Germany
| | - Y. Zha
- University of Chicago, Chicago, IL; University Hospital of Erlangen, Erlangen, Germany
| | - B. Thurner
- University of Chicago, Chicago, IL; University Hospital of Erlangen, Erlangen, Germany
| | - G. Schuler
- University of Chicago, Chicago, IL; University Hospital of Erlangen, Erlangen, Germany
| |
Collapse
|
40
|
Zou J, Sun Q, Akiba S, Yuan Y, Zha Y, Tao Z, Wei L, Sugahara T. A case-control study of nasopharyngeal carcinoma in the high background radiation areas of Yangjiang, China. J Radiat Res 2000; 41 Suppl:53-62. [PMID: 11142212 DOI: 10.1269/jrr.41.s53] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
The main purposes of this study were to identify the major determinants of nasopharyngeal carcinoma (NPC) in the high-background radiation areas (HBRA) in Yangjiang, China and to evaluate their potential confounding effects on the NPC risk associated with exposure to high background radiation. A matched case-control study was conducted using those who died of NPC during the period 1987-1995. Two controls were randomly selected for each case from those who died from causes other than malignancies and external causes. Cases and their controls were matched with respect to sex and the years of birth and death (+/- 5 years). Study subjects' next-of-kin were interviewed using a standardized questionnaire to collect information on socioeconomic status, dietary habits, tobacco smoking and alcohol consumption, disease history, pesticide use, medical X-ray exposure, the family history of NPC and so on. We succeeded in interviewing 97 cases and 192 controls. Univariate conditional logistic regression analysis showed that NPC risk was associated with the consumption of salted fish, homemade pickles, and fermented soy beans, education levels, the history of chronic rhinitis, and the family history of NPC. Multivariate conditional logistic regression analysis revealed that education levels (Odds ratio (OR) for middle school or higher levels vs. no school education = 3.8, 95% CI = 1.2 to 11.8), salted fish intake (OR = 3.2, 95% CI = 1.7 to 6.1), the history of chronic rhinitis (OR = 3.6, 95% CI = 1.3 to 10.1), and the family history of NPC (OR = 14.2, 95% CI = 2.7 to 73.4) were independent risk factors of NPC. Tobacco smoking (OR = 1.2, 95% CI = 0.7 to 2.1), and alcohol consumption (OR = 0.9, 95% CI = 0.5 to 1.9) were not significantly related to NPC risk. The ORs of NPC risk comparing HBRA and a nearby control area before and after adjustment for the major risk determinants identified in the present study were 0.86 (95% CI = 0.50 to 1.50) and 0.87 (95% CI = 0.45 to 1.67), respectively. Salted fish intake was a strong risk factor of NPC. Education, the history of chronic rhinitis and the family history of NPC were also related to NPC risk. The exposure to high background radiation in HBRA of Yangjiang was not related to NPC risk with or without the adjustment for those major risk determinants of NPC.
Collapse
Affiliation(s)
- J Zou
- Guangdong Institute of Prevention and Treatment of Occupational Diseases, 165 Xingangxi Road, Guangzhou 510310, China
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Tao Z, Zha Y, Akiba S, Sun Q, Zou J, Li J, Liu Y, Kato H, Sugahara T, Wei L. Cancer mortality in the high background radiation areas of Yangjiang, China during the period between 1979 and 1995. J Radiat Res 2000; 41 Suppl:31-41. [PMID: 11142210 DOI: 10.1269/jrr.41.s31] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
The objective of the present study was to estimate cancer risk associated with the low-level radiation exposure of an average annual effective dose of 6.4 mSv (including internal exposure) in the high background-radiation areas (HBRA) in Yangjiang, China. The mortality survey consisted of two steps, i.e., the follow-up of cohort members and the ascertainment of causes of death. The cohort members in HBRA were divided into three dose-groups on the basis of environmental dose-rates per year. The mortality experiences of those three dose groups were compared with those in the residents of control areas by means of relative risk (RR). During the period 1987-1995, we observed 926,226 person-years by following up 106,517 subjects in the cohort study, and accumulated 5,161 deaths, among which 557 were from cancers. We did not observe an increase in cancer mortality in HBRA (RR = 0.96, 96% CI, 0.80 to 1.15). The combined data for the period 1979-95 included 125,079 subjects and accumulated 1,698,316 person-years, observed 10,415 total deaths and 1,003 cancer deaths. The relative risk of all cancers for whole HBRA as compared with the control area was estimated to be 0.99 (95% CI, 0.87 to 1.14). The relative risks of cancers of the stomach, colon, liver, lung, bone, female breast and thyroid within whole HBRA were less than one, while the risks for leukemia, cancers of the nasopharynx, esophagus, rectum, pancreas, skin, cervix uteri, brain and central nervous system, and malignant lymphoma were larger than one. None of them were significantly different from RR = 1. Neither homogeneity tests nor trend tests revealed any statistically significant relationship between cancer risk and radiation dose. We did not find any increased cancer risk associated with the high levels of natural radiation in HBRA. On the contrary, the mortality of all cancers in HBRA was generally lower than that in the control area, but not statistically significant.
Collapse
Affiliation(s)
- Z Tao
- Laboratory of Industrial Hygiene, Ministry of Health, Beijing 100088, China.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Sun Q, Akiba S, Tao Z, Yuan Y, Zou J, Morishima H, Kato H, Zha Y, Sugahara T, Wei L. Excess relative risk of solid cancer mortality after prolonged exposure to naturally occurring high background radiation in Yangjiang, China. J Radiat Res 2000; 41 Suppl:43-52. [PMID: 11142211 DOI: 10.1269/jrr.41.s43] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
A study was made on cancer mortality in the high-background radiation areas of Yangjiang, China. Based on hamlet-specific environmental doses and sex- and age-specific occupancy factors, cumulative doses were calculated for each subject. In this article, we describe how the indirect estimation was made on individual dose and the methodology used to estimate radiation risk. Then, assuming a linear dose response relationship and using cancer mortality data for the period 1979-1995, we estimate the excess relative risk per Sievert for solid cancer to be -0.11 (95% CI, -0.67, 0.69). Also, we estimate the excess relative risks of four leading cancers in the study areas, i.e., cancers of the liver, nasopharynx, lung and stomach. In addition, we evaluate the effects of possible bias on our risk estimation.
Collapse
Affiliation(s)
- Q Sun
- Laboratory of Industrial Hygiene, Ministry of Health, No. 2 Xinkang Street, Deshengmenwai, Beijing 100088, China.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Zha Y, Lin C, Liang X. [The use of gene gun in cancer gene therapy]. Zhonghua Yi Xue Za Zhi 2000; 80:522-5. [PMID: 11798811] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
OBJECTIVE With Helios gene gun, the report genes EGFP and Lac-Z were transfected to several cultured mammalian tumor cell lines in vitro and mice skin in vivo, respectively. A stable long time exogene's expression were got. Then, the pWRG3142, which carried mGM-CSF gene was delivered to the abdominal skin of C57BL/6 mice using gene gun. Pathological sections showed the local transproteins' expression companying with a profound inflammation reaction characterized by neutrophilic infiltration. ELISA assay of transfected mouse's serum sample indicated a high improvement of transgenic proteins level, which demonstrated that transgenic GM-CSF secreted from treated skin into the bloodstream effectively. In B16 melanoma tumor model, mice immunized with mGM-CSF expression plasmids could be partially protected from 1 x 10(5) B16 cells challenge and exhibited a drastically reduced tumor growth rate. Finally, we conclucled that exogenes could be transfected into cultured cell lines and mice skin effectively by gene gun technology, and gene gun mediated in vivo delivery of GM-CSF cDNA should be further developed for potential clinical testing as an approach for human cancer gene therapy.
Collapse
Affiliation(s)
- Y Zha
- National Lab of Molecule Oncology, Cancer Institute, PUMC & CAMS, Beijing, 100021 China
| | | | | |
Collapse
|
44
|
Mayhew E, Ahmad I, Bhatia S, Dause R, Filep J, Janoff AS, Kaisheva E, Perkins WR, Zha Y, Franklin JC. Stability of association of 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine with liposomes is composition dependent. Biochim Biophys Acta 1997; 1329:139-48. [PMID: 9370251 DOI: 10.1016/s0005-2736(97)00102-8] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The ether lipid, 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine (ET-18-OCH3), has anticancer activity, but it has serious side-effects, including hemolysis, which prevent its optimal use. We surmised if ET-18-OCH3 could be stably associated with liposomes, less free ET-18-OCH3 would be available for lytic interaction with red cells. Liposome composition variables investigated included acyl chain saturation, phospholipid head group and mole ratio of Chol and ET-18-OCH3. It was found that attenuation of hemolysis was strongly liposome composition dependent. Some ET-18-OCH3 liposome compositions were minimally hemolytic. For example, whereas the HI5 (drug concentration required to cause 5% human red cell lysis) was 5-6 microM for free ET-18-OCH3, it was approximately 250 microM for DOPC (dioleoylphosphatidylcholine):Chol (cholesterol):DOPE-GA (glutaric acid derivatized DOPE):ET-18-OCH3, (4:3:1:2) and 640 microM for DOPE (dioleyolphosphatidylethanolamine):Chol:DOPE-GA:ET-18-OCH3 (4:3:1:2) liposomes. Efflux of carboxyfluorescein (CF) from liposomes and Langmuir trough determinations of mean molecular area of lipids in monolayers (MMAM) were used as indicators of membrane packing and stability. Incorporation of ET-18-OCH3 in liposomes reduced the MMAM. Reduction in CF permeation was correlated with reduction in hemolysis. The most stable liposomes included components, such as cholesterol, DOPC and DOPE, which have complementary shapes to ET-18-OCH3.
Collapse
Affiliation(s)
- E Mayhew
- The Liposome Company Inc., Princeton Forrestal Center, NJ 08540-6619, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Perkins WR, Dause RB, Li X, Franklin JC, Cabral-Lilly DJ, Zha Y, Dank EH, Mayhew E, Janoff AS. Combination of antitumor ether lipid with lipids of complementary molecular shape reduces its hemolytic activity. Biochim Biophys Acta 1997; 1327:61-8. [PMID: 9247167 DOI: 10.1016/s0005-2736(97)00043-6] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Because the therapeutic use of the antitumor ether lipid 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphorylcholine (ET-18-OCH3) is restricted by its hemolytic activity we explored the use of lipid packing parameters to reduce this toxicity by creating structurally optimized ET-18-OCH3 liposomes. We postulated that combination of ET-18-OCH3, which is similar in structure to lysophosphatidylcholine, with lipid molecules of complementary molecular shape (opposite headgroup/chain volume) would likely yield a stable lamellar phase from which ET-18-OCH3 exchange to red blood cell membranes would be curtailed. To quantitate the degree of shape complementarity, we used a Langmuir trough and measured the mean molecular area per molecule (MMAM) for monolayers comprised of ET-18-OCH3, the host lipids, and binary mixtures of varying mole percentage ET-18-OCH3. The degree of complementarity was taken as the reduction in MMAM from the value expected based on simple additivity of the individual components. The greatest degree of shape complementarity was observed with cholesterol: the order of complementarity for the ET-18-OCH3-lipid mixtures examined was cholesterol >> DOPE > POPC approximately DOPC. Phosphorus NMR and TLC analysis of aqueous suspensions of ET-18-OCH3 (40 mol%) with the host lipids revealed them to all be lamellar phase. For ET-18-OCH3 at 40 mol% in liposomes, the hemolytic activity followed the trend of the reduction in MMAM and was least for the ET-18-OCH3/cholesterol system (H50 = 661 microM ET-18-OCH3) followed by ET-18-OCH3/DOPE (H50 = 91 microM) and mixtures with POPC and DOPC which were comparable at H50 = 26 microM and 38 microM, respectively: the H50 concentration for free ET-18-OCH3 was 16 microM. This experimental strategy for designing optimized liposomes with a reduction in exchange, and hence toxicity, may be useful for other amphipathic/lipophilic drugs that are dimensionally compatible with lipid bilayers.
Collapse
Affiliation(s)
- W R Perkins
- The Liposome Company, Inc., Princeton, New Jersey 08540, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Ahmad I, Filep JJ, Franklin JC, Janoff AS, Masters GR, Pattassery J, Peters A, Schupsky JJ, Zha Y, Mayhew E. Enhanced therapeutic effects of liposome-associated 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine. Cancer Res 1997; 57:1915-21. [PMID: 9157985] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The ether-lipid 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine (ET-18-OCH3) has anticancer activity, but systemic toxicity has restricted its therapeutic use. In this report "free" ET-18-OCH3 and a stable, well-characterized, liposome-based formulation of ET-18-OCH3 (ELL-12) were compared for in vivo toxicity in normal mice and for therapeutic efficacy in three mouse tumor model systems. The entrapment of ET-18-OCH3 in liposomes decreased the acute toxicity of ET-18-OCH3 after i.v. administration. The maximum tolerated dose for a single i.v. dose of free ET-18-OCH3 was found to be approximately 25 mg/kg, whereas the maximum tolerated dose for ELL-12 was approximately 200 mg/kg. ELL-12 was much less hemolytic in vivo than ET-18-OCH3. The therapeutic efficacy of free ET-18-OCH3 and ELL-12 was investigated against i.p. P388 leukemia, Lewis lung cancer lung metastases, and B16/F10 melanoma (lung tumor nodules) in mice. Although ET-18-OCH3 had some anticancer activity, it was found that ELL-12 was more effective than ET-18-OCH3 in all three tumor models at lower and nontoxic dose schedules. These results suggest that association of ET-18-OCH3 in stable, well-characterized liposomes transforms it into an effective antitumor agent.
Collapse
Affiliation(s)
- I Ahmad
- The Liposome Company, Inc., Princeton, New Jersey 08540, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Zha Y, Barzykin V, Pines D. NMR and neutron-scattering experiments on the cuprate superconductors: A critical re-examination. Phys Rev B Condens Matter 1996; 54:7561-7574. [PMID: 9984383 DOI: 10.1103/physrevb.54.7561] [Citation(s) in RCA: 51] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/12/2023]
|
48
|
|
49
|
Liu DZ, Zha Y, Levin K. Theory of neutron scattering in the normal and superconducting states of YBa2Cu3O6+x. Phys Rev Lett 1995; 75:4130-4133. [PMID: 10059822 DOI: 10.1103/physrevlett.75.4130] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
|
50
|
Zha Y, Levin K, Liu DZ. Collective modes and implications for c-axis optical experiments in layered cuprates. Phys Rev B Condens Matter 1995; 51:6602-6616. [PMID: 9977195 DOI: 10.1103/physrevb.51.6602] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/12/2023]
|